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1 Introduction 
1.1 Angiogenesis 
During embryonic development new blood vessels are formed by 
vasculogenesis and angiogenesis as the growing embryo requires oxygen and 
the transport of nutrients and waste [1-4]. During vasculogenesis a primitive 
vascular network develops in the embryo by in situ differentiation of endothelial 
cells (EC) from endothelial precursor cells (angioblasts), proliferation, and the 
assembly of EC into blood vessels including the aorta and major veins [1, 5]. 
Subsequent formation of new capillaries by sprouting or splitting from their 
vessel of origin (angiogenesis and intussusception) and remodeling are finally 
leading to a mature cardiovascular system, the first functional organ system in 
the embryo [1, 2, 4, 6, 7].  
In the adult, vessels arise mainly through angiogenesis, describing the 
development of new capillaries from pre-existing blood vessels [2, 3, 8]. 
Physiologically, angiogenesis only occurs in the female reproductive system, 
hair growth, and wound healing [9, 10]. Under pathological situations such as 
chronic inflammatory processes the quiescent vasculature is activated and new 
capillaries grow [2, 8, 11]. Abnormal vascular growth contributes to cancer and 
numerous non-neoplastic disorders such as psoriasis, rheumatoid arthritis and 
retinopathies, or may result from tissue ischemia [6, 9, 12]. 
Several steps in angiogenesis have been determined (Fig. 1): 1) Proteolytic 
degradation of the extracellular matrix (ECM), 2) chemotactic migration and 
proliferation of EC, 3) formation of vascular tube structures and functional 
remodelling of the endothelium [2, 13]. In the following, these steps are 
described more in detail. 
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Figure 1. New blood vessel formation. A, During angiogenesis blood vessels arise 
from pre-existing capillaries or post-capillary venules. B, Pericytes (green) detach and 
blood vessels dilate before proteolytic degradation of the extracellular matrix.              
C, Chemotactic migration of endothelial cells (red) towards angiogenic stimuli into the 
perivascular space is facilitated. D, Endothelial cells proliferate, loosely following each 
other. E, Endothelial cells adhere to each other, create a lumen, and build a new 
circulatory system. Finally, blood vessels need to be functionally remodelled (modified 
from Bergers [13]). 
1.1.1 The VEGF and angiopoietin family 
Mechanistically, the vascular endothelial growth factor (VEGF)/VEGF receptor 
system is required for embryonic development [7, 12, 14-18] and together with 
the angiopoietin (Ang)/Ang receptor system continues to play a critical role 
during subsequent angiogenesis [19-23].  
The VEGF family of growth factors consists of several homologues in 
mammals: VEGF-A [24], VEGF-B [25], VEGF-C [26], VEGF-D [27], and the 
placental growth factor (PIGF) [28]. Another homologous polypeptide has been 
found in the genome of the orf virus, a parapoxvirus, named VEGF-E [29]. The 
VEGFs mediate cellular responses by different high-affinity endothelial receptor 
tyrosine kinases: VEGF receptor (VEGFR)-1/fms-like tyrosine kinase (Flt)-1 
[30], VEGFR-2/fetal liver kinase (Flk)-1 in mice [31], respectively kinase insert 
domain receptor (KDR) in human [32], VEGFR-3/Flt-4 [33] and the collapsin/ 
semaphorin receptors neuropilin-1 and neuropilin-2 (co-receptors of VEGFR-2) 
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[34, 35]. The most important receptor of angiogenesis is VEGFR-2 which is 
activated by VEGF-A and VEGF-B [24]. 
The second family of growth factors are the angiopoietins. Three members have 
been discovered in mice, Ang-1 to Ang-3, and additionally Ang-4 in humans  
[12, 20, 36]. Ang-1 and Ang-2 differ in their expression pattern during 
vasculogenesis [19, 21] and angiogenesis [2] and bind primarily to the receptor 
tyrosine kinase with immunoglobulin-like and EGF-like domains (Tie)-2 [14]. 
Ligands for the highly homologous receptor Tie1 have not yet been identified 
[23, 37]. 
1.1.2 Degradation of the extracellular matrix 
Before EC can migrate from their pre-existing site, mature vessels need to be 
destabilised to become sensitive for the activity of growth and survival signals 
[3]. Therefore, VEGF induces phosphorylation of the junctional molecule 
vascular endothelial (VE)-cadherin [38], weakening interendothelial cell 
contacts. Moreover, periendothelial cells and smooth muscle cells are detached 
from the vessel. Ang-2 may be involved in this process [3, 19]. Vasodilation and 
increased vascular permeability in response to VEGF enable the extravasation 
of plasma proteins which form a matrix for migration of activated EC [3, 39]. 
Moreover, platelet endothelial cell adhesion molecule (PECAM)-1 (CD31) [40] 
and VE-Cadherin [38] are redistributed and fenestrations and ‘vesiculo-vacuolar 
organelles’ are formed, contributing to the increase in vascular permeability [3]. 
Then, the ECM is proteolytically degraded by proteinases of the chymase or 
heparanase families, the urokinase plasminogen activator (uPA), and matrix 
metalloproteinases (MMP) [3, 15, 41]. MMPs can degrade most components of 
the vascular basement membrane and the interstitial matrix such as collagen, 
laminin, fibronectin, and elastin [42]. This contributes to the release of growth 
factors sequestered within the ECM, promoting angiogenesis [43]. At the same 
time, activated EC secrete proteinase inhibitors such as plasminogen activator 
inhibitor-1 (PAI-1) to locally define this degradation [41, 44]. 
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1.1.3 Endothelial cell proliferation and migration 
Once the ECM has been degraded and a perivascular space is created, EC 
proliferate, elongate, and migrate towards angiogenic stimuli such as VEGF-A 
[45]. Moreover, angiogenic sprouting is activated by Ang-1 which furthermore 
potentiates VEGF [22, 46]. αvß3 integrin, a cell-matrix receptor for ECM 
constituents such as vitronectin, fibronectin, fibrinogen, or osteopontin, 
mediates adhesion of EC to ECM to enable migration and cell spreading         
[6, 47-49]. A balance of activators and inhibitors controls angiogenic sprouting 
[3, 13]. Thus, angiogenic inhibitors such as angiostatin (an internal fragment of 
plasminogen) [50] or endostatin (a fragment of collagen XVIII) [51] can restrain 
the proliferation and/or migration of EC [3].  
Furthermore, the VEGF-induced EC proliferation requires mitogen-activated 
protein kinase (MAPK)- and phosphoinositide 3 kinase (PI3K)-dependent 
signals [52]. MAPKs are a widely conserved family of serine/threonine protein 
kinases that regulate multiple cellular activities such as cell differentiation, 
proliferation, migration, and death. For example, the extracellular signal-
regulated kinase (ERK)1/2 or (p44/p42)-MAPK signalling pathways control the 
expression of cell-cycle regulated genes and responds to several distinct 
extracellular stimuli including cytokines, growth factors, and mitogens [53, 54]. 
The p38 MAPK or stress-activated protein kinase (SAPK)-2 is activated by 
phosphorylation and acts in a signalling cascade that controls cellular 
responses to inflammatory cytokines and environmental stress such as 
ultraviolet (UV) light and osmotic shock [53, 55]. Another key role in regulating 
cell growth and proliferation plays the PI3K target mTOR, a serine/threonine 
protein kinase which also acts as a sensor of nutrient levels [56-58]. 
1.1.4 Vascular tube formation and functional remodelling 
The EC form a migration column and adhere to each other to form a lumen and 
loops [13]. Continued proliferation of EC leads to an increase of vessel diameter 
and length which is induced by Ang-1 in combination with VEGF [3, 13, 22, 59]. 
Integrins such as αvβ3 support this lumen formation [48], whereas 
thrombospondin (TSP)-1 is an endogenous inhibitor [3]. If capillaries merge or 
additional EC join existing vessels, this process is called intercalated growth or 
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non-sprouting angiogenesis [7]. This process was first described in the 
embryonic lung [60] and is important for vessel growth in the heart and during 
healing of endothelial wounds [7, 15]. If vessels are split by pillars of the 
capillary wall, this process of blood vessel formation is called intussusceptive 
growth [2, 60, 61].  
All vessels formed are initially immature and must further develop [12]. For 
stability, vessels get surrounded by pericytes or smooth muscle cells which 
stimulate the re-establishment of the ECM [3, 62]. Proteinase inhibitors (for 
example PAI-1) prevent degradation of the provisional ECM around developing 
vessels [6]. Signalling by transforming growth factor-β1 (TGF-β1) and          
Ang-1/Tie2 stabilises the interaction between endothelial and smooth muscle 
cells and therefore protects vessels against damage [6, 22, 62]. After the onset 
of blood circulation, smooth muscle cells provide blood vessels with viscoelastic 
and vasomotor properties that are important to adapt to changes in the blood 
pressure [3, 7].  
1.1.5 Endothelial cell survival 
EC become quiescent once they are integrated in new vessels and survive for 
years [3], as they are among the longest-living cells in the body aside cells of 
the central nervous system [11]. In the adult, under normal physiological 
conditions, EC have a low turnover [63, 64] and only 0.01% of EC are 
undergoing division [6, 11]. Nevertheless, vessel regression which occurs in the 
retina and ovary after birth is caused by endothelial apoptosis [3, 65]. The lack 
of nutrients or survival signals, the increase of nitric oxide (NO) and reactive 
oxygen species (ROS), a blocked lumen, and angiogenic inhibitors such as 
angiostatin and vascular endothelial growth inhibitor (VEGI) can all induce 
endothelial apoptosis [2, 3, 17, 65]. VEGF, depending on the interaction 
between VEGFR-2, β-catenin and VE-cadherin [66], and Ang-1 act, whereas 
Ang-2 counteracts, as endothelial survival factors [3, 14, 59]. αvβ3 is a survival 
factor for angiogenic but not quiescent EC as it is only expressed in proliferative 
cells [3, 7, 47, 67].  
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1.2 Tumour angiogenesis 
Already 100 years ago, angiogenesis was observed around tumours [68, 69]. 
Like normal tissue, tumours require oxygen and nutrients for their survival and 
therefore need blood vessel structures with capillaries at a mean distance of 
100 to 200 µm - the diffusion limit for oxygen. Blood vessels enable tumours to 
grow beyond a critical size and to metastasise to another organ such as lung 
and liver [6, 70].  
There are two distinct concepts of early tumour vascularization which have 
provoked significant debates, the avascular growth of tumours and the co-
option concept, both outlined below (Fig. 2) [71].  
 
Figure 2. Models of tumour angiogenesis. A, Model of avascular tumour initiation.      
B, Tumour initiation involving host vessel co-option (according to Yancopoulos [12]). 
The avascular tumour initiation has become widely accepted, as many primary 
tumours and metastases arise avascularly and only later induce their 
vascularization [11, 12, 72, 73]. This principle has been confirmed in many 
model systems, whereby tumour cells were injected in a subcutaneous pouch or 
in another avascular site such as the cornea pocket [11, 74], thus requiring 
angiogenesis for further growth. Through these experiments it has been  
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considered that the critical size at which tumours switch to an angiogenic 
phenotype is 1-2 mm [13, 41, 73]. Through the fast tumour growth local tissue 
hypoxia is induced. This is leading to an upregulation of VEGF expression in 
tumour cells and stroma which in turn stimulates, together with Ang-2, the 
growth of blood vessels by sprouting or intussusception [75-78].  
The other concept describes that tumours initiate vascularly without inducing 
angiogenesis as they co-opt preexisting host blood vessels [12, 73]. Then, host 
vessels start to express high autocrine levels of Ang-2 and the co-opted vessels 
get apoptotic so that the tumour becomes secondarily avascular and hypoxic 
[12, 79, 80]. Hence, tumour-derived VEGF is induced and angiogenesis is 
stimulated, allowing further tumour growth [12, 79, 80]. 
1.2.1 The angiogenic switch  
Cancer cells begin to promote angiogenesis early in tumourigenesis by 
producing a ‘diffusible angiogenic substance’ later defined as VEGF [6, 81, 82] 
and hence, tumour growth and metastasis have been proposed to be 
‘angiogenesis-dependent’ [6, 72]. Activation of angiogenesis occurs in a 
process called the angiogenic switch which is associated with an imbalance of 
pro- and antiangiogenic molecules (Fig. 3) [11, 71]. On the one hand, 
proangiogenic factors such as VEGF, basic fibroblast growth factor (bFGF), 
interleukin-8 (IL-8), or PIGF are upregulated. On the other hand, angiogenesis 
suppressors such as TSP-1 are downregulated [11, 83]. Further signals 
triggering this switch include immune/inflammatory response mechanisms, 
mechanical and metabolic stress such as pressure or low pO2, and genetic 
mutations [6, 13].  
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Figure 3. The balance hypothesis for the angiogenic switch. Angiogenesis is activated 
by an angiogenic switch mechanism which is associated with an imbalance of pro- and 
antiangiogenic molecules. The switch may be kept off through the absence of 
angiogenesis inducers while in others higher levels of angiogenesis inhibitors retain the 
effects of angiogenesis inducers. Thus, either increasing the activator levels (e.g. 
induction of VEGF by hypoxia) or reducing the inhibitor concentration (e.g. of TSP-1) 
can change the balance and activate the angiogenic switch leading to the growth of 
new blood vessels (according to Hanahan [11]). 
1.2.2 Structure and function of tumour vessels 
In contrast to the normal, organised vessel network, tumour vasculature is 
unstructured, dilated, and leaky as tumour vessels mostly lack a protective coat 
of perivascular cells and smooth muscle cells, have widened interendothelial 
junctions and numerous ‘openings’ [6, 13, 39, 84, 85]. Moreover, vessels are 
tortuous and have an unsteady diameter, leading to an irregular blood flow, 
resulting in hypoxic and acidic regions in the tumour [6, 13]. In addition, vessels 
may be lined by multiple layers of EC [6, 13] and cancer cells can be integrated 
into the vessel wall (‘vasculogenic mimicry’) [86-89].  
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1.3 Angiogenesis in non-neoplastic diseases 
Hypoxia and inflammation contribute to angiogenesis in non-neoplastic 
diseases such as psoriasis or diabetes, in that vessels do not grow but rather 
abnormally remodel [6, 90, 91]. 
1.3.1 Hypoxia-induced angiogenesis 
Hypoxia is a strong stimulus for angiogenesis in numerous disorders such as 
wounds or atherosclerotic plaques, diabetes, Alzheimer’s disease, and asthma 
[6, 90]. Hypoxia-inducible factor (HIF)-1 is a transcription complex which is 
composed of HIF-1α and HIF-1β subunits. During normoxia the von Hippel-
Lindau tumour suppressor gene product regulates the HIF system by oxygen 
dependent degradation of HIF-1α [3]. Once hypoxia occurs, the degradation of 
HIF-1α is interrupted, HIF translocates into the nucleus and upregulates the 
expression of VEGF, VEGFR-1, VEGFR-2, neuropilin-1, Ang-2, nitric oxide 
synthase (NOS), tumour necrosis factor (TNF), TGF-β1, IL-8, and other target 
genes [3, 6, 90]. 
1.3.2 Inflammation-induced angiogenesis 
Prolonged and excessive angiogenesis is a distinct feature of chronic 
inflammatory disorders in many organs such as rheumatoid arthritis, asthma, 
psoriasis of the skin and joints, and also in cancer [6, 91, 92]. Several 
leukocytes including monocytes, macrophages, mast cells, and others release a 
variety of angiogenic factors including VEGF, Ang-1, TGF-α/β, TNF-α or 
platelet-derived growth factor (PDGF), various interleukins such as IL-1, IL-6, 
and IL-8, and cytotoxic mediators including ROS and proteinases [4, 6, 93, 94]. 
Wound cells such as endothelial and smooth muscle cells, fibroblasts, 
leukocytes, or platelets are attracted by some of these factors and produce 
additional angiogenic factors [6]. Morever, during inflammation, but in the 
absence of angiogenesis, vasodilation and increased permeability can be 
strong pathogenic mechanisms [6].  
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1.4 Immunotherapy 
Generation of a protective immunity against different diseases is the classical 
aim of immunotherapy. In active immunotherapy, therapeutic immunity is 
triggered by antigen administration using adjuvants such as immunostimulatory 
cytosine-phosphorothioate-guanine (CpG) containing DNA or the keyhole limpet 
hemocyanin (KLH) [95]. In passive immunotherapy, ex vivo generated, specific 
T cells are adoptively transferred [95, 96]. Moreover, monoclonal antibodies 
directed against cell surface antigens such as the human epidermal growth 
factor receptor (Her)2/neu, the human epithelial cell adhesion molecule EpCAM 
(CD326), or other target antigens are applied in immunotherapy [95, 97]. These 
antibodies directly target cancer cells by complement mediated cytolysis and 
can be conjugated with toxins, radionuclides or chemotherapeutic drugs [98]. 
Moreover, the antibody-dependent cellular cytotoxity (ADCC) mediated by 
natural killer (NK) cells results in apoptosis of cancer cells [98]. 
1.4.1 Active immunotherapy 
Active immunisation or vaccination with major histocompatibility complex (MHC) 
class I-restricted tumour antigens is used in tumour immune therapy of mice 
and humans, but still, the therapeutic effect is limited [99-101]. It has been 
described that vaccination efficiency can be improved by tumour antigen-loaded 
dendritic antigen presenting cells (APC) and genetically modified tumour cells    
[99, 100, 102]. Moreover, stimulating T cells through CD28/CTLA-4 (cytotoxic      
T lymphocyte antigen-4) or increasing CD4+ T helper (Th) cell activity can 
increase vaccination effectiveness, but altogether these approaches raise the 
risk that autoimmune disease may occur [99]. Moreover, vaccination with 
tumour antigens following an adoptive cell transfer may enhance therapeutic 
efficiency in mouse models of tumour therapy [103, 104].  
1.4.2 Passive cellular immunotherapy 
At the moment, adoptive T cell therapy (ACT) is studied for the treatment of 
both, infectious (cytomegalovirus (CMV), human immunodeficiency virus (HIV), 
Epstein-Barr virus (EBV)) and malignant (melanoma, leukemia) diseases in  
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humans [95, 105-111]. In mouse models, tumour-specific T cells, after ex vivo 
activation, expansion, and selection, are adoptively transferred into tumour 
bearing mice for the treatment of established experimental tumours [106]. This 
approach has been extensively analysed and was shown to be very successful 
in tumour therapy [95, 103, 104, 106, 112-115]. Through therapy of transplanted 
syngeneic tumours with splenocytes from immunised mice in early ACT studies, 
the characteristics of transferred T cells were defined [106]. Nowadays, most 
studies use T cell receptor (TCR)-transgenic mouse models in order to study 
the exact mechanisms by which T cells eliminate large established tumours  
[96, 103, 106, 116, 117].  
1.4.3 CD4+ and CD8+ T cells in ACT 
CD4+ and CD8+ T cells detect tumour cells through the recognition of MHC-I 
and MHC-II-restricted tumour-specific antigens by the TCR [118, 119]. Through 
changes in the cell metabolism, multiple tumour-associated antigens are 
expressed during the development of malignant tumours [118, 119]. 
 
Figure 4. Activation of T effector cells. A, Th cells express the T cell receptor and the 
CD4 co-receptor and recognize antigens which are presented on MHC class II 
molecules on the cell surface of antigen presenting cells. A second signal for activation 
of Th cells is provided by the co-stimulatory molecules CD28 and B7 (CD80/CD86).    
B, Cytotoxic T lymphocytes (CTL) express the TCR and the CD8 co-receptor. They 
recognize target cells which present cytosolic antigens on their surface MHC class I 
molecules (modified from Janeway [120] and Jung [121]). 
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1.4.3.1 Immunotherapy with CD8+ T cells 
CD8+ T cells recognize target antigens from intracellular proteins presented in 
an MHC class I-restricted manner and thus may activate tumour-specific CD8+ 
T cells [118, 122]. Exogenous antigens may also be presented by MHC class I 
molecules on bone marrow (BM)-derived APC a process that is called 
crosspresentation [122, 123]. Moreover, CD8+ cytotoxic T lymphocytes (CTL) 
have the ability to lyse tumour cells by direct cell-to-cell contact [122, 124]. 
Accordingly, it has been shown that CTL are effective in rejecting implanted 
tumours, even in the absence of CD4+ T cells [111, 125-128]. Surprisingly, most 
transfer experiments with TCR transgeneic CD8+ T cells were ineffective 
without the addition of other help mechanisms [125, 128-132]. Nevertheless, 
most adoptive transfer studies keep on focusing on tumour-specific CD8+          
T cells [129].  
1.4.3.2 Immunotherapy with CD4+ T cells 
Antigens presented by MHC class II molecules on APC are recognized by CD4+ 
T cells [118, 122]. Although many class II peptides could be characterised from 
primary solid tumours, so far, only a few MHC class II-restricted tumour-specific 
antigens have been identified as highly immunogenic peptides [133-136]. CD4+ 
T cells can directly lyse tumour cells expressing MHC class II in the rare case of 
lymphomas [99, 137]. Yet, most tumours are MHC class II negative [134]. 
Nevertheless, over the last 30 years several experiments have shown that CD4+ 
T cells themselves can control tumours in a dose dependent manner and 
almost completely independently of CD8+ T cells [99, 115, 117, 122, 129, 138-
140]. Surprisingly, it was demonstrated that CD4+ T cells are even more 
effective than CD8+ T cells in eliminating several different tumours, even when 
the lytic activity of CD4+ T cells against tumour cells in vitro or in vivo was very 
low and tumour cells lacked MHC expression [129, 141, 142]. Although the 
CD4+ T cells could act independently of CD8+ T cells [129], it was essential that 
they did interact with other host cells, in particular with NK cells [99, 117, 141] or 
macrophages [117, 129, 139, 143, 144]. These data suggest that CD4+ T cells 
may be potent effector cells that are able to reject a broad range of tumours. 
However, current studies keep on analysing tumour-specific CD4+ T cells 
mainly for their role in helping CTL to kill tumour cells [123, 129, 140, 145].  
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1.4.3.3 CD4+ T cells in the antitumour immune response 
CD4+ T cells have several functions in the development of an antitumour 
response but it still remains elusive how CD4+ T cells control tumour growth 
[117, 122]. During the priming phase of an immune response CD4+ T cells 
provide costimulatory signals for the priming of MHC class I-restricted CD8+ 
CTL and help CTL to develop [122, 145]. APC may present tumour antigens in 
the context of MHC class II molecules to tumour-specific CD4+ T cells leading to 
a reciprocal activation of APC and T cells by CD40/CD40L interactions what is 
necessary for further CTL crosspriming [117, 122, 140, 146, 147].  
Moreover, CD4+ T cells are required in the effector phase of an antitumour 
immune response [122]. This was shown by depletion studies [113, 122, 139] 
and by adoptive transfer experiments [138, 139], demonstrating that tumour 
rejection required CD4+ T cells. It has been proposed that memory CD4+ T cells 
are activated by APC and induce a delayed type hypersensitivity reaction 
(DTHR) [148]. Consequently, through the release of cytokines, CD4+ T cells 
recruit and activate inflammatory cells such as macrophages, granulocytes, or 
NK cells to mediate antitumour effects [113, 122, 139, 149].  
Furthermore, CD4+ T cells secrete cytokines such as IL-2 which are necessary 
for the proliferation and survival of CTL [105, 122, 150, 151]. Accordingly, it was 
shown that after the transfer of mixed CD4+/CD8+ T cell lines in the treatment of 
EBV-induced lymphoma, the viability of transferred EBV-specific CD8+ CTL was 
maintained for many months [95, 122]. Interferon (IFN)-γ (see 1.4.4.1.1) 
provided by CD4+ Th1 cells inhibits tumour angiogenesis and is crucial for 
tumour rejection [122, 142, 152]. 
1.4.3.4 T cell subpopulations 
CD4+ T cells play a significant role in orchestrating antitumour immunity        
[99, 152] and can be divided into Th1, Th2, Th17 cells, and regulatory T cells 
(Treg) based on the profile of transcription factors and secreted cytokines        
[139, 148, 153, 154]. Th1 cells mainly produce high levels of the 
proinflammatory cytokines IFN-γ and IL-2 [148, 152]. The Th1 commitment 
depends on activation of T-bet by locally produced IL-12 (see 1.4.4.1.2) [155].  
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Th2 cells mainly produce IL-4, IL-5, IL-10, and IL-13 after TCR stimulation and 
activation of GATA3 by IL-4 [148, 153]. Both, Th1 and Th2 cells, are derived 
from a common precursor [156]. Th1 cells activate APC, secrete cytokines 
which are important for the eradication of intracellular pathogens, and mediate 
DTHR whereas Th2 cells play a predominant role in humoral responses      
[148, 157]. In contrast to Th2 cells, Th1 cells promote the generation of memory 
responses against intracellular pathogens [152, 155, 158]. So, specifically 
directing the Th1 cell responses against a tumour antigen could be a safe and 
effective approach to immune based tumour therapies [158].  
Recently, a new distinct subset, unrelated to Th1 and Th2 cells, has been called 
Th17 [159-162]. Th17 cells produce mainly IL-17A (IL-17) and IL-17F (see 
1.4.4.1.3), develop from naïve CD4+ T cells when stimulated in the presence of 
TGF-β and IL-6, and require IL-23 (see 1.4.4.1.2) for population expansion and 
as survival factor [163-165]. The orphan nuclear receptor RORγt has been 
identified to direct the Th17 generation [166]. Th17 cells have been associated 
with many inflammatory autoimmune diseases such as asthma [167], psoriasis 
[168], and experimental autoimmune encephalomyelitis (EAE) [169], but also 
with the inhibition of tumour growth mediated by the production of IL-17 [170]. 
Therefore, Th17 cells might also be useful for immunotherapy of cancer.  
1.4.4 Other factors relevant for tumour rejection 
Recent evidence suggests that a potent tumour antigen, together with activated 
T cells, is not sufficient for tumour rejection and that tumour immunity cannot 
entirely depend on direct tumour cell killing [122, 171]. Actually, it is very likely 
that cytokines produced by effector CD4+ T cells and a permissive tumour 
microenvironment are required to achieve a successful therapy [171, 172]. 
Indeed, experimental studies showed the ‘interdependence of CD4+/CD8+         
T cell-mediated immunity and cytokine-driven innate immune responses’, anti-
angiogenesis, and the host environment [122, 132, 142, 152, 173-178].  
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1.4.4.1 Cytokines involved in tumour rejection  
1.4.4.1.1 Interferon-γ 
It has been proposed that in vivo IFN-γ secretion by CD4+ T cells is important to 
allow subsequent tumour rejection [142, 179-182]. Evidence came from 
experiments showing that the generation of a T cell dependent tumour immunity 
is reduced in IFN-γ-deficient (IFN-γ-/-) [130, 132, 139] and IFN-γ-receptor-
deficient (IFN-γR-/-) mice [122, 131, 176]. Besides Th1 cells, mainly CD8+ T cells 
and NK cells produce IFN-γ which is an important effector molecule in cell-
mediated immunity and necessary for Th1 development [148, 183-185]. As the 
IFN-γR is expressed on almost every cell type, IFN-γ exerts various biological 
activities on different cell types [122, 176, 183, 186]. IFN-γ, together with TNF-α 
released from activated macrophages, shows cytotoxic effects on tumour cells 
[122, 187] and inhibits tumour cell proliferation [188]. Moreover, IFN-γ enhances 
MHC class I and II expression, resulting in increased tumour cell recognition 
and killing [122, 180, 189, 190]. Additionally, IFN-γ activates innate immune 
cells such as macrophages, mast cells, dendritic cells (DC), and NK cells within 
the tumour stroma to mediate tumour rejection [122, 173, 191]. By inhibiting the 
production of immunosuppressive molecules such as TGF-β, IFN-γ may also 
exert immunomodulatory effects [122, 152]. Tumour angiogenesis can also be 
inhibited through IFN-γ secretion by CD4+ T cells as IFN-γ induces the 
expression of angiogenesis inhibitors such as the chemokines Interferon-
inducible protein 10 (IP-10 or CXCL10) and monokine-induced by IFN-γ (Mig or 
CXCL9) in tumour cells and macrophages [192-195]. 
1.4.4.1.2 IL-6 cytokine family: IL-12, IL-23, IL-27 
These type I cytokines are a superfamily of immunomodulators [196]. IL-12 was 
initially identified as a NK cell stimulatory factor [197] and cytotoxic lymphocyte 
maturation factor [198-200]. IL-23 [201] and IL-27 [202] were cloned by 
homology searches for members of the IL-6 family in DNA sequence databases 
[199]. IL-12, IL-23, and IL-27 are heterodimeric cytokines: IL-12 is composed of 
an α-chain (p35 subunit) and a β-chain (p40 subunit) [200]. IL-23 consists of the  
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p40 subunit of IL-12 and a novel subunit p19 [201]. The subunits of IL-27 are 
p28 and EBV-induced-gene (Ebi)-3 [202]. The monomeric ligands IL-12/p35,  
IL-23/p19, and IL-27/p28 are functionally inactive [199-202]. Hence, the 
heterodimers must be expressed in the same cell to generate active cytokines 
[199]. Nevertheless, it has been shown that transgenic overexpression of        
IL-23/p19 in mice can result in severe inflammation and death at 3 months of 
age [196, 203]. 
IL-12 signals through the IL-12 receptor complex that is composed of the        
IL-12Rβ1 and IL-12Rβ2 chains [204]. The IL-23 receptor complex consists of 
the IL-12Rβ1 chain and a novel receptor chain, IL-23R [205]. The receptor of  
IL-27 is composed of WSX-1/TCCR and gp130 [206]. The receptor complexes 
are expressed by macrophages, DC, NK cells, and activated T cells. In CD4+    
T cells the expression levels vary strongly, depending on the maturation and 
differentiation status of the T cells [204-206]. 
The structural similarity among IL-12, IL-23, and IL-27 is reflected in overlapping 
roles, though these cytokines are not functionally redundant [196, 199, 207, 
208]. Activated monocytes, macrophages, and DC mainly produce these 
cytokines in response to microbial and host immune stimuli [196, 199]. They are 
important in regulating T cell proliferation and cytokine production, the activation 
of NK cells, and B cell antibody production [199, 208].  
Nevertheless, there are differences: IL-12 induces IFN-γ secretion in freshly 
activated naïve T and NK cells and promotes the differentiation to Th1 cells 
[199, 209]. It is critical for the establishment of resistance to infections with 
viruses, intracellular mycobacteria, and parasites by inducing optimal IFN-γ 
secretion, expansion, and activation of T cells [210]. Its role in autoimmune 
diseases such as collagen-induced arthritis (CIA) or EAE is controversial [211]. 
IL-12 also shows potent antitumour activity in a variety of murine tumour models 
of established tumours and metastases [212-215]. Nevertheless, the 
mechanisms by which IL-12 controls tumour growth are still not fully defined, 
but it seems that the following processes play an important role:                       
1) antiangiogenesis through the induction of IFN-γ and antiangiogenic 
chemokines (IP-10/CXCL10, Mig/CXCL9) which might have direct effects on EC  
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proliferation and differentiation [181, 215-218], 2) destruction of tumour vessels 
by NK cell cytotoxicity or by direct lymphocyte-endothelial cell interactions, 
independently of IFN-γ [215, 219-221], and 3) activation of CTL, antitumour 
antibodies, or leukocytes which may produce proinflammatory cytokines      
[215, 220].  
IL-23 also costimulates IFN-γ production from CD4+ T and NK cells but is not as 
efficient as IL-12 [199, 201]. In contrast, IL-23 has the unique activity to induce 
strong proliferation of memory T cells [199, 222]. Thus, IL-23 is important in the 
later stages of Th cell development [223]. In comparison to IL-12, IL-23 is 
essential for the induction and maintenance of brain and joint inflammation 
autoimmune diseases such as CIA or EAE [169, 211] as it drives the survival of 
Th17 cells. Similar to IL-12, IL-23 may exert antitumour and antimetastatic 
activity in murine models of cancer [223-226]. However, the antitumour activity 
of IL-23 seems to be independent of IFN-γ as it was effective in mice depleted 
of IFN-γ [226]. Moreover, besides CD8+ and CD4+ T cells IL-23 seems to 
require NK cells, macrophages, and DC for its antiumour activity and it is 
suggested that the expression of IL-12, TNF-α, and NO contributes to the 
antitumour effect of IL-23 [223-226].  
Like IL-12, IL-27 is able to induce proliferation of naïve T cell populations    
[199, 227, 228]. Thus, on the one hand, IL-27 promotes expansion of antigen-
specific CD4+ T cells, supports Th1 polarisation, and type I inflammation     
[202, 228, 229]. On the other hand, IL-27 is described as a suppressor of 
inflammatory responses [230-232]. IL-27 may increase antitumour activity which 
is mainly mediated through infiltrating CD8+ T cells with enhanced tumour-
specific CTL activity or NK cells [224, 233-236]. Moreover, IL-27 induces the 
expression of MHC class I molecules and INF-γ [224, 236]. Hence, IL-27 
produces T cell-dependent and -independent antitumour effects. Moreover, it 
shows antiangiogenic properties due to the induction of IP-10/CXCL10 and 
Mig/CXCL9 and has therapeutic potential in cancer therapy similar to IL-12 
[234, 237].  
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1.4.4.1.3 IL-17 
IL-17 (IL-17A) was first identified as CTLA-8 [238] and is a member of a 
cytokine family consisting of IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (IL-25), and 
IL-17F [239-241]. IL-17 acts as a proinflammatory cytokine as it stimulates 
endothelial, fibroblastic, and epithelial cells to secrete other inflammatory 
cytokines such as IL-6 and IL-8 [240, 242, 243]. It also costimulates T cells and 
supports T cell responses especially through the induction of the intracellular 
adhesion molecule-1 (ICAM-1 or CD54) which interacts with blood leukocytes 
[159, 161, 239]. IL-17 is critical for antibacterial immunity in mice [244] and has 
been associated with chronic inflammatory diseases including rheumatoid 
arthritis [245], bronchial asthma [167], and systemic sclerosis [246]. IL-17 also 
may exert antitumoural activities [170]. 
1.4.4.2 Role of the tumour environment in tumour rejection 
To create a permissive and supportive environment for tumour development, 
cancer cells themselves modify their adjacent stroma by producing a variety of 
growth factors and proteases [91, 92, 247]. These factors induce angiogenesis 
and activate surrounding stromal cells such as fibroblasts and smooth muscle 
cells that in turn secrete further growth factors and proteases [247]. Supported 
by neutrophils, DC, monocytes/macrophages, eosinophils, mast cells, and 
lymphocytes [248, 249], intra-tumoural inflammation also promotes 
angiogenesis and progressive tumour growth [92, 177, 247, 250]. 
It has been suggested that modifying this tumour microenvironment and 
stimulating the infiltration of effector cells can improve T cell therapy and 
diminish tumour progression [171, 174, 251, 252]. In support of this idea, 
irradiation of transgenic mice led to tumour rejection that was mediated by 
lymphocytic infiltration and a proinflammatory environment [171, 174, 252]. 
Moreover, it has been shown that a complete tumour eradication was achieved 
through combination of irradiation and multiple T cell transfers, whereas 
treatment with tumour-specific T cells alone had no effect on tumour growth 
[171]. Similarly, it was demonstrated in several mouse models that previous 
immune suppression modifies the tumour environment and therefore improves 
the efficacy of transferred cells [107, 253].  
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1.5 Dimethylfumarate used in psoriasis treatment and its 
effects on endothelial cells and angiogenesis 
1.5.1 Pathogenesis of Psoriasis 
Psoriasis is a chronic inflammatory autoimmune disease of skin and small 
joints. The formation of erythematous plaques, infiltrated by IFN-γ producing 
Th1 cells, neutrophils, and mast cells, is a characteristic feature of psoriasis of 
the skin [254]. The critical role of the Th1-mediated inflammatory response in 
the pathogenesis of psoriasis is demonstrated through several therapies leading 
to clinical improvement of the disease: inhibition of T cell activation by 
recombinant proteins [255], reduction of activated T cells or suppression of       
T cell cytokine production through treatment with immunosuppressive agents 
including cyclosporine A [256] and methotrexate [257], or by Th2-inducing 
therapeutics [258]. Moreover, elevated expression of TNF-α in psoriatic skin 
lesions [259] and successful treatment of psoriasis with TNF-α blockers [260] 
suggest a central role for TNF-α in the disease. An increased expression of a 
variety of inflammation maintaining mediators such as IFN-γ, TNF-α, IL-17,     
IL-19, IL-23, IL-12, IL-8, VEGF, and others was shown in lesional skin and 
peripheral blood of psoriasis patients [258, 261]. Moreover, the tissue 
inflammation is closely associated with a strong induction of an angiogenic 
response, resulting in elongated, tortuous, and dilated vessels in the papillary 
dermis [262-265]. Elevated VEGF [266] and IL-8 [267] expression levels by 
hyperproliferating epidermal keratinocytes and an upregulation of VEGFR-1 and 
VEGFR-2 on EC of the superficial microvasculature in psoriatic skin may 
contribute to this neovessel formation during psoriasis [268]. Moreover, an 
increased expression of EC stimulating angiogenesis factor (ESAF) [266] and 
HIF-1α/HIF-2α [269] was demonstrated in psoriatic plaques. The EC also show 
an increase in αvβ3 integrin expression [270], and proliferation [265]. Moreover, 
reduced levels of the antiangiogenic factor TSP1 were found [267]. Together, 
these data suggest a critical role for angiogenesis in the pathogenesis of 
psoriasis.  
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1.5.2 Angiogenesis and reactive oxygen species 
ROS are the most important class of radical species produced in the cellular 
metabolism [271]. The superoxide anion radical (O2.-) has been described as 
the first ROS formed. It can further interact with other molecules to 
subsequently generate additional ROS such as hydroxyl radicals [271]. The 
superoxide radical is formed mostly within the cell mitochondria by reduction of 
molecular oxygen mediated by nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases [272] or non-enzymatically [271]. It is dismutated by the 
superoxide dismutase (SOD) to hydrogen peroxide [271, 273]. Other defence 
mechanisms against the accumulation of ROS include enzymatic antioxidants 
such as catalase [273], glutathione peroxidase (GPx)-1 [274], and non-
enzymatic antioxidants such as glutathione (GSH) [275] and the synthetic       
N-Acetylcysteine (NAC). ROS induce cell type and stimulus specific cellular 
responses. At increased physiological levels, ROS are capable to cause 
proangiogenic responses such as EC proliferation, migration, and survival     
[94, 271, 276]. In contrast, high concentrations of ROS result in cell death 
through the induction of apoptosis or necrosis [271, 276]. Endothelial injury 
caused by ROS is involved in a variety of vascular diseases such as 
atherosclerosis, cardiomyopathy, and hypertension [271, 277-279]. 
1.5.3 Dimethylfumarate in the treatment of psoriasis 
For the treatment of severe psoriasis, fumaric acid esters (FAE) have been 
used since 1959 [280] and at present FAE are approved in Germany [281]. A 
defined mixture of FAE containing dimethylfumarate (DMF) and the main active 
metabolite methylhydrogenfumarate (MHF) is used for treatment [281]. 
However, the mechanisms underlying of the antipsoriatic effect are not fully 
understood. Besides the inhibition of Th1 cytokine production [282, 283] and the 
upregulation of Th2 cytokines [284, 285] in vitro and in vivo, it has been shown 
that DMF inhibits chemokine secretion by keratinocytes and peripheral blood 
mononuclear cells [286]. Furthermore, the cytokine-induced expression of 
several adhesion molecules such as E-selectin, ICAM-1, and the vascular cell 
adhesion molecule-1 (VCAM-1 or CD106) that are typically found in activated 
endothelium of blood vessels in psoriatic skin [287, 288], is restrained [289]. 
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Accordingly, the nuclear translocation of the vertebrate transcription factor 
nuclear factor (NF)κB in EC may be prevented by DMF [290]. NFκB regulates 
the expression of genes involved in cell growth and survival [291]. Importantly, 
DMF modulates the intracellular redox status by decreasing the level of GSH, a 
tripeptide consisting of glutamate, cysteine, and glycine (γ-Glu-CysH-Gly)    
[275, 282]. GSH functions as intracellular scavenger of ROS and as central 
redox buffer of the cell [271, 275, 292]. Moreover, additional reducing 
equivalents provided by both GSH and glutaredoxin are needed for DNA 
synthesis as DNA polymerase alpha and ribonucleotide reductase are thiol 
dependent enzymes [275, 292-295]. However, the mechanisms by which DMF 
might influence angiogenesis as a crucial component in the pathogenesis of 
psoriasis remain elusive.  
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1.6 Aims and objectives of the dissertation 
1.6.1 Tumour immunotherapy 
Adoptive cell transfer therapies led to an improvement in the outcomes for 
patients in recent clinic studies. However, little progress has been made in the 
description and generation of in vivo effective tumour-antigen specific T cells 
and the identification of the exact mechanisms by which these T cells eliminate 
large, established tumours in mice or in humans. Therefore, the following 
objectives have been set out:  
1) Analysing mechanisms of a specific Th1 cell therapy, directed against the 
human tumour-associated antigen EpCAM 
2) Analysing the role of cytokines, the host environment and antiangiogenic 
mediators 
3) Optimisation of the Th1 cell therapy 
 
1.6.2 Effects of DMF on angiogenesis 
FAE therapeutics containing DMF as the main component are approved and 
well established for the therapy of severe psoriasis. However, the underlying 
mechanisms of the antipsoriatic effect are not fully understood. Since 
angiogenesis is supposed to be a critical component in the pathogenesis of 
psoriasis the following objectives have been defined: 
1) Investigation of the effects of DMF regarding EC function in vitro  
2) Identification of possible underlying signal transduction pathways 
3) Analysing the effects of DMF on angiogenesis in vivo  
 
Materials and Methods 
23 
2 Materials and Methods 
2.1 Equipment 
 
Table 1. Equipment used for experiments. 
Instrument Type Company 
Balances Precision scale CP224SOCE 
Laboratory scale EW1500-2M 
Sartorius, Göttingen  
Kern, Balingen-Frommern 
β counter Micro Beta Trilux Perkin Elmer, Rodgau-
Jügesheim 
Cell harvester Filter Mate Perkin Elmer, Rodgau-
Jügesheim 
CO2 humidified 
incubator 
Heracell 240 Thermo/Kendro, 
Dreieich/Hanau 
Centrifuges Biofuge pico Heraeus  
Biofuge fresco Heraeus 
Multifuge 3S-R Heraeus 
Thermo/Kendro, 
Dreieich/Hanau  
Cryotome SME Thermo Shandon, Dreieich 
ELISA-Reader Molecular Devices Emax MWG Biotech, Ebersberg 
FACS Calibur  
LSRII 
Becton Dickinson, 
Heidelberg  
Gel electro-
phoresis 
Vertical gel: Protean II 
                  Model 45-2020i 
Horizontal gel: 
                 Model SUB Cell GT 
                 Model Gel XL Plus 
BioRad, München  
Peqlab, Erlangen  
 
BioRad, München  
Labnet, Ried 
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Instrument Type Company 
Heating blocks Thermomixer Model Comfort 
Model LS2 
Eppendorf, Hamburg  
VLM, Leipoldshöhe 
Medimax Medimax Keul, Steinfurt 
Microscopes Axiovert25 Invers  
Axiovert200 Fluorescence 
HBO100 
Zeiss, Jena 
Mixer Mill  MM300 Retsch, Haan 
PCR machine  Mastercycler gradient  
Primus 96 plus  
iCycler 584BR02280 
Eppendorf, Hamburg  
MWG Biotech, Ebersberg  
BioRad, München 
pH meter CG842 Schott, Wertheim 
Phosphoimager Storm 860 Amersham/Pharmacia 
Biotech, Freiburg 
Photometer BioPhotometer 6131 Eppendorf, Hamburg 
Pipettors Model Research  
Model Reference  
Pipette boy 
Eppendorf, Hamburg 
Eppendorf, Hamburg 
Hirschmann Eberstadt 
Power supplies Model EPS 300  
PowerPac 300 Power Supply 
PowerPac Basic Power Supply 
Pharmacia Biotech, Freiburg 
BioRad, München  
BioRad, München 
Rotary 
microtom 
2040 Reichert-Jung, Nußloch 
Semidry 
Transblot 
Fastblot B44 Biometra, Göttingen 
Shaker STR8 Rocking Platform Stuart Scientific, Darmstadt 
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Instrument Type Company 
Software Cell Quest Pro  
FCS Express software 
  
Image Quant 5.1 
BD Bioscience, Heidelberg 
DeNovoSoftware, Ontario, 
Canada 
MolecularDynamics 
Tissue culture 
hood 
HeraSafe KS18 Thermo/Kendro, 
Dreieich/Hanau 
Tissue 
embedding and 
staining 
systems 
Hypercenter XP  
Tissue Embedding System 
TES99  
24 Stainer 
Varistain 24-4 
Promounter RCM90 
Automatic coverslipping 
machine 
Shandon, Frankfurt/Main 
Medite GmbH, Burgdorf  
 
Shandon, Frankfurt/Main 
Shandon, Frankfurt/Main 
Medite GmbH, Burgdorf 
Medite GmbH, Burgdorf 
UV trans-
illuminator 
RH-5.1 darkroom hood with 
easy 442K camera 
Herolab, Wiesloch 
Vortex mixer   Reax Top Heidolph, Kelheim 
Water bath Model WB22 Funke Medingen, Freital 
2.2 Materials  
All sterile plastic materials for cell culture and screw-cap tubes (15 ml, 50 ml) 
were purchased from Greiner (Frickenhausen). FACS tubes, microcentrifuge 
and PCR tubes (0.2-2.0 ml) were from BD Falcon (Heidelberg).  
2.3 Reagents, standards, and enzymes 
Reagents used were ordered in high purity grade (puriss. p.A. or for 
microbiology) from the following companies, if not otherwise stated: Amersham 
Biosciences (Braunschweig), BD Biosciences (Heidelberg), Gibco/Invitrogen 
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(Karlsruhe), Merck/VWR (Darmstadt), Roth (Karlsruhe), Serva (Heidelberg), 
and SigmaAldrich/Fluka/RiedeldeHaen (Taufkirchen).  
Cell culture products were purchased from BD Bioscience (Heidelberg), 
Biochrom AG (Berlin), BioWhittaker/Cambrex (Verviers, Belgium), Gibco/ 
Invitrogen (Karlsruhe), PAA (Cölbe), Promocell (Heidelberg), Roth (Karlsruhe), 
and SigmaAldrich/Fluka/RiedeldeHaen (Taufkirchen). Filter membranes with 
0.22 µm pore size (Millipore, Schwalbach) were used for sterilisation purposes 
of cell culture reagents and Milli-Q-purified water (dH2O) was used throughout 
the protocols. The following DNA ladders, protein standards (Table 2), and 
modified enzymes (Table 3) were used: 
 
Table 2. DNA ladders and protein standards. 
Ladder or standard Company 
Gene Ruler 100 bp DNA Ladder Fermentas, St. Leon-Rot 
Gene Ruler 1 kb DNA Ladder Fermentas, St. Leon-Rot 
Magic Mark XP Western Protein Standard Invitrogen, Karlsruhe 
SeeBlue Plus2 Pre-Stained Standard, 
‘High Range’ 
Invitrogen, Karlsruhe 
 
Table 3. Modified enzymes. 
Enzymes Company 
Accutase PAA, Cölbe 
Collagenase D Roche, Mannheim 
DNAse I, RNase free Invitrogen, Karlsruhe 
M-MLV Reverse Transcriptase (200 U/µl) Promega, Madison, USA 
Proteinase K Roche, Mannheim 
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Enzymes Company 
Recombinant RNAsin Ribonuclease 
Inhibitor (40 U/µl) 
Promega, Madison, USA 
RNase A Boehringer, Mannheim 
Taq Core Kit-Taq-DNA-Polymerase MP Biomedicals, Irvine, USA 
 
2.4 Primary antibodies 
2.4.1 For cell culture 
Table 4. Primary antibodies for cell culture. 
Antibody Characteristics Reference or company 
Anti-CD4 (L3T4), anti-
CD8 (Ly2), MAR 
(mouse anti-rat) 
Hybridoma Gift from Prof. Schmidt 
(IMSB, Mainz) 
Anti-IFN-γ (XMG-1.2) Purified antibody Gift from Prof. Mocikat 
(GSF, Munich) 
Anti-IL-4 (11B11) Hybridoma Gift from Prof. Schmidt 
(IMSB, Mainz) 
 
 
2.4.2 For Fluorescence activated cell sorting (FACS) analysis 
Table 5. Primary antibodies for FACS analysis. 
Antibody Characteristics Reference or company 
Anti-mouse CD4 
(RM4-5) 
FITC-conjugated 
monoclonal rat antibody 
BioLegend/Biozol, Eching 
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Antibody Characteristics Reference or company 
Anti-mouse CD8 (Ly2) FITC-conjugated 
monoclonal rat antibody 
BD Bioscience/Pharmingen 
Heidelberg 
Anti-mouse CD11b 
(Mac-1 α chain) 
FITC-conjugated 
monoclonal rat antibody 
BD Bioscience/Pharmingen 
Heidelberg 
Anti-mouse DO-11.10 
TCR (KJ1-26) 
FITC-conjugated 
monoclonal rat antibody 
Caltag, Hamburg 
Rat IgG2a (RTK2758) FITC-conjugated rat IgG 
isotyp 
BioLegend/Biozol, Eching 
Anti-mouse IFN-γ 
(XMG1.2) 
PE-conjugated 
monoclonal rat antibody 
BioLegend/Biozol, Eching 
Anti-mouse IL-4 
(11B11) 
PE-conjugated 
monoclonal rat antibody 
BioLegend/Biozol, Eching 
Anti-mouse IL-10 
(JES5-16E3) 
PE-conjugated 
monoclonal rat antibody 
BD Bioscience/Pharmingen, 
Heidelberg 
Anti-mouse IL-17 
(TC11-18H10) 
PE-conjugated 
monoclonal rat antibody 
BD Bioscience, Heidelberg 
Rat IgG1 (RTK2071) PE-conjugated rat IgG 
isotyp 
BioLegend/Biozol, Eching 
Anti-mouse CD11c 
(N418) 
APC-conjugated 
monoclonal hamster 
antibody 
Caltag, Hamburg 
Hamster IgG APC-conjugated hamster 
IgG isotyp 
BioLegend/Biozol, Eching 
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2.4.3 For immunohistochemistry 
Table 6. Primary antibodies for immunohistochemistry. 
Antibody Characteristics Reference or company 
Anti-mouse CD11b 
(Mac-1α chain) 
Monoclonal rat antibody BD Bioscience/Pharmingen, 
Heidelberg 
Anti-mouse Ki-67 
(Tec3)  
Monoclonal rat antibody DakoCytomation, Hamburg 
Anti-mouse PECAM-1 
CD31 (MEC 13.3) 
Monoclonal rat antibody BD Bioscience/Pharmingen, 
Heidelberg 
Anti-mouse VEGFR-2 
Flk-1 (C-1158) 
Monoclonal rat antibody Santa Cruz, Heidelberg 
Anti-mouse CD4 
(L3T4) 
Biotin-conjugated 
monoclonal rat antibody 
BD Bioscience/Pharmingen, 
Heidelberg 
Anti-mouse F4/80 
(BM8) 
Biotin-conjugated 
monoclonal rat antibody 
BMA Biomedicals, Augst, 
Switzerland 
Purified rat IgG2a  Monoclonal IgG isotyp BD Bioscience, Heidelberg 
 
2.4.4 For Western blot 
Table 7. Primary antibodies for Western blot. 
Antibody Characteristics Reference or company 
Anti-p38, p-p38 (Thr180/Tyr182) 
MAP Kinase  
Polyclonal rabbit 
antibody 
Cell Signalling/NEB, 
Frankfurt/Main 
Anti-p42/44, p-p42/44 
(Thr202/Tyr204) MAP Kinase 
Polyclonal rabbit 
antibody 
Cell Signalling/NEB, 
Frankfurt/Main 
Anti-mTor, p-mTor (Ser2448) 
Ser/Thr protein kinase 
Polyclonal rabbit 
antibody 
Cell Signalling/NEB, 
Frankfurt/Main 
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2.5 Secondary antibodies 
Table 8. Secondary antibodies. 
Antibody Characteristics Reference or company 
Donkey anti-rat IgG Cy3-conjugated antibody MolecularProbes/Dianova, 
Hamburg 
Goat anti-rabbit IgG Alkaline phosphatase-
conjugated goat IgG 
(H+L) antibody 
Amersham Biosciences, 
Braunschweig 
Goat anti-rat IgG Biotin-conjugated goat 
IgG (H+L) antibody  
VectorLab/Linaris, 
Wertheim-Bettingen 
Streptavidin PE-conjugated antibody BD Bioscience/Pharmingen, 
Heidelberg 
Yopro-1 Nucleus staining MolecularProbes/Dianova, 
Hamburg 
 
2.6 Mice 
Female wildtype (WT) BALB/c mice and BALB/c DO11.10 TCR-transgenic 
mice, specific for the chicken ovalbumin (OVA) peptide (OVA323-339), were 
purchased from Charles River Laboratories (Wilmington). IL4-/- BALB/c mice 
were kindly provided by Dr. M. Kopf (ETH, Zürich) [296]. The animals were 
maintained in the animal facilities of the Eberhard Karls University Tübingen 
under specific pathogen-free conditions. All experiments were performed 
according to the guidelines of the Institutional Animal Care and Use Committee 
of the Regierungspräsidium Tübingen. 
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2.7 Cell culture  
Eukaryotic cells were cultured in appropriate cell culture media (Table 9) at 
37°C in a 7.5% CO2 humidified incubator. Adherent cells such as the colon 
carcinoma cell line CT26, expressing the human EpCAM (CT26-EpCAM), were 
grown to confluency, washed with phosphate buffered saline (PBS), and cells 
were dispersed by trypsin/EDTA treatment (1 ml for 75 cm2 tissue culture flask). 
After washing with media (1100-1500 revolutions per minute (rpm), 5 min, room 
temperature (RT)) dissociated cells were reseeded into a fresh culture flask, 
representing a passage (p). For passaging of suspension cultures cells were 
pelleted, resuspended, and reseeded in a new flask. Cell suspensions were 
seeded in a 1:3 up to 1:15 dilution according to the growth rate of the cells. 
Human umbilical vein endothelial cells (HUVEC) and human lung-derived 
microvascular endothelial cells (HLMEC) were grown on gelatine-coated flasks 
and seeded in a 1:3 dilution. To determine the number of living cells in culture, 
cells were counted in a hemacytometer (Neubauer) using trypan blue exclusion.  
 
Table 9. Cell culture media. 
Cell line Reference or company Cell culture media 
CT26-EpCAM Gift from Prof. Mocikat  
(GSF, Munich) 
Dulbecco’s modified Eagles Media 
(DMEM, 4.5 g glucose) 
10% (v/v) fetal calf serum (FCS) 
1% (v/v) Pen/Strep (Stock solution:
             10000 U/ml penicillin-G  
             10000 µg/ml streptomycin 
Primary T cells Freshly isolated DMEM (4.5 g glucose)  
10% (v/v) FCS  
1% (v/v) Pen/Strep 
10 µM HEPES-Buffer 
1% (v/v) MEM amino acids 
1 mM sodium pyruvate 
40 µM 2-mercaptoethanol 
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Cell line Reference or company Cell culture medium 
HUVEC Promocell MCDB131 media 
8% (v/v) FCS 
2% (v/v) human serum 
1% (v/v) Pen/Strep 
2.5 µg/ml amphotericin B  
4 mM glutamine  
10 µg/ml heparin 
0.4% (v/v) endothelial cell growth 
                 supplement (ECGS) 
HLMEC Promocell MCDB131 media 
5% (v/v) FCS 
5% (v/v) human serum 
1% (v/v) Pen/Strep 
2.5 µg/ml amphotericin B 
4 mM glutamine  
40 µg/ml heparin 
0.4% (v/v) ECGS 
2 ng/ml VEGF 
 
2.8 Long-time storage of eukaryotic cells (Cryopreservation) 
Cells to be frozen were pelleted, resuspended in FCS containing 10% (v/v) 
dimethyl sulfoxide (DMSO), aliquoted to cryovials, and transferred in a freezing 
container (Mr. Frosty, Nalgene Labware) to a −80°C freezer. For long-time 
storage cells were maintained in a liquid nitrogen freezer.  
For reuse, cells were quickly thawed in a 37°C water bath and resuspended in 
prewarmed cell culture media. After centrifugation, cells were resuspended in 
medium and transferred to a tissue culture flask. Medium was changed the next 
day. 
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2.9 Preparation of antigen presenting cells 
APC were isolated from splenocytes of WT syngeneic mice. Spleens of mice 
were harvested and placed in a 200 µm nylon mesh (2 spleens/mesh) in a petri 
dish containing 5 ml culture medium. Using the plunger of a syringe, tissue was 
pressed through the mash until mostly fibrous tissue remained. After washing, 
cells were centrifuged (1500 rpm, 5 min, RT). For removal of erythrocytes ACK 
lysis buffer (BioWhittaker) was added, cells were incubated for 2 min at RT, and 
centrifuged (1500 rpm, 5 min, RT). Afterwards, cells were washed twice with 
culture medium. Cells were T cell depleted by using anti-CD4, anti-CD8, and 
mouse anti-rat antibody (MAR) hybridomas together with rabbit complement-MA 
(Biozol) in FCS-free media and incubated for 45 min at 37°C. Cells were 
washed twice with culture medium and irradiated (30 Gy). After another 
washing step, living APC were counted and used for stimulation of T cell 
cultures. 
2.10 Immunisation and in vitro T cell differentiation of EpCAM-
reactive T helper cells 
IL4-/- BALB/c mice were immunised subcutanously with 1.0 x 106 CT26-EpCAM 
cells dispended in 50 µl CpG1668 (200 µM, 5’-tcc atg acg ttc ctg atg ct-3’, PTO 
oligo, MWG). After 10 days mice were boosted the same way. Spleen and 
lymphnodes (LN) were isolated 6 days later. Removed organs were pressed 
through a 200 µm nylon mash for single cell suspension and erythrocytes were 
lysed (see 2.9). Afterwards, cells were washed twice with culture medium. Cells 
were counted and CD4+ T cells were islolated using mouse anti-CD4 (L3T4) 
magnetic beads and LS columns to reach a purity of ~ 96% according to 
manufacturer’s instructions (MACS, Miltenyi Biotech, Bergisch Gladbach). For 
Th1 polarisation, 0.5 x 106 EpCAM-reactive CD4+ T cells were stimulated with 
1.0 x 106 APC, 1 µg/ml EpCAM protein (s17-1A, gift from Prof. Kopp, Institute of 
Immunology, Munich) and 0.2 µM CpG1668 in a 96-well plate. For Th17 
polarisation, 10 µg/ml anti-IFN-γ (XMG-1.2) antibody was added additionally to 
this setup. For T cell expansion, cultures were supplemented with IL-2          
(25-50 U/ml, Chiron Therapeutics) every 3-4 days. 
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2.11 In vitro T cell differentiation of OVA-specific T helper cells 
For OVA T cell culture, CD4+ T cells were isolated from DO11.10 transgenic 
mice as described above (see 2.10). For Th1 polarisation, 0.25 x 106 OVA  
CD4+ T cells were stimulated with 0.5 x 106 APC, 0.2 µM CpG1668, 5 µg/ml 
OVA peptide (OVA323-339: ISQAVHAAHAEINEAGR, EMC microcollections), and 
2 µg/ml murine anti-IL-4 (11B11) antibody in a 96-well plate.  
2.12 Experimental procedure of the Th1 cell therapy 
CT26-EpCAM cells were harvested and washed twice with PBS. Living cells 
(1.5 x 106) dispended in 50 µl PBS were injected subcutanously in the right and 
left flank of WT BALB/c mice (day 0) which were narcotised with ketanest   
(15% (v/v) ketamin (50 mg/ml, DeltaSelect), 8% (v/v) rompun (Bayer) in PBS). 
The mice were irradiated (2 Gy) on day 3 to induce mild inflammation. On     
day 4, cultured Th1 cells (5 x 106 cells in 250 µl PBS) were adoptively 
transferred intraperitoneally into these mice. The control group received PBS. 
Mice were sacrificed by CO2 asphyxiation at the indicated points in time and 
tumours were harvested for further analysis.  
In a further approach, one group of mice received 500 µg murine anti-IFN-γ 
antibody intraperitoneally on day 3 after irradiation and before adoptive transfer 
of T cells on day 4, as indicated. 
2.13 Fluorescence activated cell sorting 
Fluorescence activated cell sorting (FACS) has two general applications - 
quantitative analysis and cell separation. Flow cytometers use one or more 
laser sources for scanning and excitation of fluorescent probes. Fluorescence 
stimulation of fluorescent-labeled antibodies is used for quantitative analysis of 
the expression and the density of cell surface and intracellular molecules. 
Moreover, characterisation of cell size, cell volume, and different cell types in 
heterogeneous populations is possible and the purity of subpopulations can be 
evaluated. Electronic cell sorting can be used to separate distinct 
subpopulations of cells on the basis of these measured characteristics 
(according to [297]).  
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2.13.1 Intracellular FACS staining of T cells 
For polyclonal T cell stimulation, 1.0 x 106 T cells were activated in 1 ml culture 
medium with 30 ng/ml phorbol 12-myristate 13-acetate (PMA), a protein    
kinase C activator, and 1.5 mg/ml ionomycin, a Ca2+ ionophore, at 37°C in a  
24-well plate. After 2 h, cells were treated with brefeldin A (concentration as 
instructed, BD Biosciences) which is an inhibitor of protein transport, leading to 
an increased accumulation of cytokine proteins within the cells. Another 2 h 
later, cells were washed with PBS, centrifuged (300 g, 10 min), and fixed in       
2% (v/v) formaldehyde in PBS for 20 min at RT. After membranes were 
permeabilized by washing cells twice with flow cytometry buffer (0.5% (w/v) 
bovine serum albumin (BSA), 0.5% (w/v) saponin in PBS) [298, 299], 100 µl of 
the cell suspension were transferred to a FACS tube (2 x 105 cells per staining).   
20 µl of diluted (1:100) antibodies were added to the suspension and cells were 
stained for 10 min at RT in the dark for intracellular IFN-γ (XMG-1.2), IL-4, IL-10, 
or IL-17 in combination with surface CD4 (RM4-5). To determine the degree of 
background caused by non-specific binding of the heavy chain of the antibody, 
cells were also stained with IgG matched isotypes. Unstained cells were used to 
establish levels of background autofluorescence. After incubation, cells were 
washed with flow cytometry buffer and resuspended in 1% (w/v) BSA in PBS for 
FACS analysis. 10000 cells were aquired on the FACSCalibur and analysed 
using Cell Quest Pro software. 
2.13.2 FACS analysis of tumour tissue cells 
Tumour infiltrating cells were characterised by FACS analysis. Therefore, 
tumours were excised on days 10, 13, and 18 after tumour cell injection. 
Tumours from single mice were pooled and cut with Medimax. After washing 
the suspension with PBS, remaining tissue was digested for 30 min at 37°C 
using collagenase D (1 mg/ml) with 0.6 mM CaCl2 in PBS. To stop the enzyme 
activity, cells were washed with PBS containing 10% (v/v) FCS. The suspension 
was poured through a 200 µm nylon mesh which was rinsed with PBS 
containing 10% (v/v) FCS afterwards. The remaining single cell suspension was 
washed with 1% (v/v) FCS in PBS. Cells were stained using the following anti-
mouse antibodies, respectively: Fluorescein isothiocyanate (FITC)-CD4    
(RM4-5, 1:100), phycoerythrin (PE)-CD8 (Ly.2, 1:100), FITC-CD11b (Mac-1, 
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1:100), allophycocyanin (APC)-CD11c (N418, 1:200), or biotinylated anti-mouse 
F4/80 (1:150) with a secondary PE-labeled streptavidin antibody (1:1000) and 
the corresponding isotype rat IgG antibodies. After staining, cells were washed 
and resuspended in 1% (v/v) FCS in PBS for FACS analysis. 30000 cells were 
acquired on the LSRII and analysed using FCS Express software. Total living 
cells were gated by forward/sideward scatter and infiltrating cells were 
calculated on the basis of 10000 living cells. 
2.13.3 Apoptosis detection in HUVEC  
The early phases of the apoptotic program lead to a loss of membrane 
asymmetry. In apoptotic cells the membrane phospholipid phosphatidylserine 
(PS) is translocated from the inner to the outer plasma membrane and is 
therefore exposed to the external cellular environment. Thus, Annexin V, a Ca2+ 
dependent phospholipid-binding protein, is able to bind to PS as sign of an early 
stage of apoptosis. Through staining cells in conjunction with the vital dye 
propidium iodide (PI), the apoptotic state of cells can be differentiated       
(Table 10) according to the manufacturer’s instructions (BD Biosciences). 
 
Table 10. The apoptotic state of cells. 
State of cells Annexin V-FITC staining PI-staining  
Viable cells negative negative 
Early apoptotic cells positive negative 
Late apoptotic or dead cells positive positive 
 
To assay apoptosis in HUVEC (p3, p4, p5) following DMF treatment, cells were 
seeded at 1.5 x 105 cells/well in a 6-well plate in triplicates. The next day 
medium was changed containing the given DMF concentrations. DMSO treated 
cells served as negative control. To detect apoptotic cells 24 h later, adherent 
cells were dispersed by trypsin/EDTA treatment combined with the supernatant 
and treated as described in the manufacturer’s instructions (BD Biosciences) for 
subsequent FACS analysis. 
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2.13.4 Reactive oxygen species detection in HUVEC  
Derivatives of reduced fluorescein can be used as cell-permeant indicator for 
ROS (OxyBURST Green, H2DCFDA, Molecular Probes/ Invitrogen). Till acetate 
groups are removed by intracellular esterases and oxidation occurs within the 
cells, the chemically reduced and acetylated forms of 2’,7’-Dichloro-fluorescein 
are non-fluorescent. Therefore, the oxidation of the probe can be detected by 
monitoring the increase in fluorescence by flow cytometry according to the 
manufacturer’s instructions (Molecular Probes/ Invitrogen).  
For detection of ROS in HUVEC (p3, p4, p5), cells were grown to confluency in 
triplicates and incubated for 1.5 h with the appropriate concentrations of DMF 
and/or NAC; MCDB131 medium alone served as negative control. Cells were 
stained with 0.75 mM OxyBURST Green for 0.5 h. Cells were dispersed by 
accutase treatment, washed with PBS, and subsequent FACS analysis was 
performed.  
2.13.5 Cell cycle analysis of HUVEC  
One method for analysing cellular DNA content uses PI to reveal the distribution 
of cells within the major phases of the cell cycle (G0/G1 versus S versus G2/M) 
[300]. PI intercalates into double-stranded (ds) DNA and RNA and produces a 
highly fluorescent adduct with excitation at 488-600 nm. 
HUVEC (p3, p4, p5) were seeded at 1.5 x 106 cells/well in a 6-well plate in 
triplicates and the next day medium was changed containing different 
concentrations of DMF and/or NAC; MCDB131 medium alone served as 
negative control. After two days, cells were dispersed by accutase treatment, 
fixed, and permeabilized on ice for 30 min using 100% ethanol. After washing 
cells twice with ice cold PBS (2500 rpm, 5 min), cells were stained with 400 µl 
propidium iodide solution (20 µg/ml PI, 1 µg/ml RNase I in PBS). After 30 min 
on ice fluorescence was measured for cell cycle analysis.  
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2.14 RNA and DNA 
2.14.1 Preparation of RNA and cDNA from tumour tissue 
Total RNA was isolated from whole tumour tissue using the Mixer Mill (30 Hz,   
2 x 30 sec, Retsch) and purified according to manufacturer’s instructions 
(Macherey-Nagel). RNA was eluted in 30 µl RNA-free water. 1 µg RNA was 
digested with DNAse I according to manufacturer’s instructions (Invitrogen) and 
converted to cDNA using M-MLV reverse transcriptase (RT, Table 11). 
 
Table 11. cDNA synthesis. 
Step Mixture Treatment 
I 1 µg RNA 
0.5 µM oligo dT 
0.5 mM dNTPs (dATP, dTTP, dCTP, dGTP)
dH2O ad 15 µl  
5 min, 70°C 
on ice 
II 5 µl 5x buffer 
3.5 µl H2O 
0.5 µl RNAsin (20 U) 
2 min, 37°C 
III ± 1 µl M-MLV RT (200 U) 60 min, 37°C 
15 min, 70°C 
 
2.14.2 Spectrophotometric quantitation of RNA and DNA  
For quantitation of nucleic acids absorbance measurements (A260 nm for RNA 
and DNA) were performed with a photometer. The ratio of A260/A280 was used 
as an indicator of nucleic acid purity. Ratios of 1.8 to 1.9 and 1.9 to 2.0 indicate 
highly purified preparations of DNA and RNA, respectively. Contaminants that 
absorb at 280 nm (e.g. proteins) will lower this ratio (according to [301]).  
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The following nucleic acid concentration in water can be expected with an 
optical density, OD = 1 (according to R. Heidenreich): 
 
Table 12. Nucleic acid concentration in water. 
Property Absorbance (A260), OD = 1 
DNA, double-stranded 50 µg/ml 
DNA, single-stranded about 30 µg/ml 
RNA 40 µg/ml 
 
2.14.3 Monitoring separation of DNA through agarose gels 
Agarose gel electrophoresis is a highly effective method for separating, 
identifying, and purifying DNA fragments. DNA molecules exposed to an electric 
field (voltage: 35-135 V) migrate from the cathode toward the anode due to the 
negatively charged phosphates along the DNA backbone. The electrophoretic 
separation depends on charge and/or size of macromolecules. Fragments travel 
through the gel matrices at a rate that is inversely proportional to the log10 of 
their molecular weight. Therefore, the molecular weight of a fragment can be 
determined by using DNA standards of known molecular weight (e.g. 1 kb 
ladder). For visualisation of DNA fragments, ethidium bromide was used since 
the dye intercalates between the stacked bases of nucleic acids and when 
illuminated with UV light (260-360 nm), ethidium bromide gives a red-orange 
fluorescence (560 nm). A UV transilluminator was used for DNA visualisation 
and photography (according to [302]).  
For gel electrophoresis concentrations of 0.5% to 2.0% (w/v) agarose in         
0.5 x Tris-acetate-EDTA (TAE) electrophoresis buffer were used to separate  
0.2-0.6 kb fragments. Agarose powder was melted in 0.5 x TAE buffer, cooled, 
and 0.5 µg/ml ethidium bromide was added into the gel. The melted agarose 
was poured into the gel casting platform and the gel comb inserted. After the gel 
has hardened, the gel comb was withdrawn, the gel was set in the 
electrophoresis tank, and covered with 0.5 x TAE buffer. DNA samples with      
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2 x loading buffer were loaded into the wells as progress of the separation can 
be monitored by the migration of the dyes in the loading buffer. 
 
Table 13. Buffers used for agarose gel electrophoresis. 
0.5 x TAE electrophoresis buffer  40 mM Tris 
5.7% (v/v) acetic acid 
0.8 mM EDTA 
dH2O 
2 x loading buffer 50% (v/v) glycerin 
0.2% (w/v) Orange G 
TAE electrophoresis buffer 
 
2.15 The polymerase chain reaction 
The polymerase chain reaction (PCR) is an in vitro method for specifically 
amplifying DNA fragments enzymatically. Therefore, the standard PCR mixture 
(Table 14) was cycled 20-35 times through temperatures that permit 
denaturation (95°C), annealing (about 5°C below melting point of primers), and 
synthesis of the specific PCR product (72°C, elongation). PCR parameters are 
dependent on 1) the sequence, length, and amount of the template DNA, 2) the 
sequence, GC content and percent complementarity of the primers, and 3) the 
efficiency of the reaction. The PCR products were visualized on an appropriate 
agarose gel.  
Table 14. PCR protocols. 
Standard PCR mixture 50-100 ng template cDNA  
0.2 mM dNTPs (dATP, dTTP, dCTP, dGTP) 
0.5 µM primer forward 
0.5 µM primer reverse 
2.0 µl 10x Taq buffer 
0.2 µl Taq polymerase (1-2 U) 
dH2O ad 20 µl 
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Standard PCR protocol 94°C, 3 min 
(94°C, 40 sec, variable, 40 sec, 72°C, 40 sec) 20-35 x
72°C, 3 min 
8°C, hold 
 
The following primers were used for standard PCR: 
 
Table 15. Primers used for standard PCR. 
Gen Sequence Annea-
ling 
Size 
(bp) 
GAPDH 5’-CTCACTCAAGATTGTCAGCAATG-3’ (forward)
5’-GAGGGAGATGCTCAGTGTTGG-3’ (reverse) 
59 669 
Aldolase 5’-AGCTGTCTGACATCGCTCACCG-3’ (forward) 
5’-CACATACTGGCAGCGCTTCAAG-3’ (reverse) 
59 600 
Ang-1 5’-GGGGGAGGTTGGACAGTAAT-3’ (forward) 
5’-CGAACCACCAACCTCCTGTT-3’ (reverse) 
54 388 
Ang-2 5’-GTCCATGAAGGAGCAGAAGG-3’ (forward) 
5’-GCCTTGATCTCCTCTGTGGA-3’ (reverse) 
51 312 
CXCR3 5’-CAGCCTGAACTTTGACAGAACCT-3’ (forward)
5’-GCAGCCCCAGCAAGAAGA-3’ (reverse) 
51 287 
Mig/ 
CXCL9 
5’-TTTTCCTTTTGGGCATCATCTT-3’ (forward) 
5’-AGCATCGTGCATTCCTTATCACT-3’ (reverse) 
59 75 
PIGF 5’-CAGGTCCTAGCTGGGTTGG-3’ (forward) 
5’-TCACGGGTGGGGTTCC-3’ (reverse) 
56 441 
VEGFR-2 5’-TTCTGGACTCTCCCTGCCTA-3’ (forward) 
5’-GACTGGTAGCCACTGGTCTG-3’ (reverse) 
59 354 
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2.16 Quantitative real-time PCR  
For quantitative real-time (RT)-PCR specific amplification of a gene of interest 
was performed by mixing template DNA, two appropriate oligonucleotide 
primers (0.1-0.2 µM), and the iQTM SYBR Green Supermix (BioRad). The mix 
contains thermostable iTaqTM DNA polymerase, dNTPs, buffer, and SYBR 
Green I, which is a fluorescent dye that directly intercalates in double-stranded 
(ds) DNA according to manufacturer’s instructions (BioRad). The dye generates 
a signal that is proportional to the accumulating dsDNA concentration and can 
be detected using the iCycler iQ instrument. Dependent on the primers     
(Table 16), a standard protocol with parameters similar to standard PCR was 
used and multiplex reactions were run in triplicates (Table 17). For analysing 
the specifity of the PCR reaction a melting curve was recorded. After user 
defined adjustment of the threshold position to 50, crossing points (Cp) of 
samples were used to calculate gene expression.  
Normalising the gene of interest expression values to the internal HPRT control 
in every sample and considering the amplification efficiency of the different 
primers, the arbitrary expression units were calculated as follows: 
Arbitrary expression = Gen
HPRT
Cp
Gen
Cp
HPRT
x
x
;     X: tested primer efficiency 
The relative expression of genes of interest is represented as fold differences of 
the mean of treated tumour samples to the mean of control tumour samples. 
Relative expression = 
controlcontrol
treatedtreated
nAE
nAE
∑
∑
;    n: number of tumours 
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The following sequences were used for RT-PCR:  
 
Table 16. Primer sequences used for RT-PCR. 
Gen Sequence Annea-
ling 
(°C) 
Size 
(bp)
HPRT 5’-GTTCTTTGCTGACCTGCTGGAT-3’ (forward)  
5’-CTTAGGCTTTGTATTTGGCTTT-3’ (reverse) 
59 440
IL-23/p19 5’-CATGGAGCAACTTCACACCTC-3’ (forward) 
5’-GGTGATCCTCTGGCTGGA-3’ (reverse) 
62 63 
IL-12/p35 5’-ATGACCCTGTGCCTTGGTAG-3’ (forward) 
5’-CAGATAGCCCATCACCCTGT-3’ (reverse) 
59 289
IFN-γ 5’-TCAAGTGGCATAGATGTGGAAGAA-3’ (forward) 
5’-TGGCTCTGCAGGATTTTCATG-3’ (reverse) 
59 92 
ICAM 5’-CCTGTTTCCTGCCTCTGAAG-3’ (forward)  
5’-GTCTGCTGAGACCCCTCTTG-3’ (reverse) 
59 528
IL-6 5’-CCGGAGAGGAGACTTCACAG-3’ (forward) 
5’-CAGAATTGCCATTGCACAAC-3’ (reverse) 
56 120
IL-27/Ebi3 5’-GCTCCCCTGGTTACACTGAA-3’ (forward) 
5’-ACCGAGAAGCATGGCATT-3’ (reverse) 
59 72 
IL-17 5’-TCAGACTACCTCAACCGTTCC-3’ (forward) 
5’-CTTTCCCTCCGCATTGACAC-3’ (reverse) 
61 126
IL-12/p40 5’-CAGTACACCTGCCACAAAGGAGGC-3’ (forward) 
5’-GTCCAGTGTGACCTTCTCTGCAGACA-3’ (reverse) 
62 264
IL-27/p28 5’-CCCAATGTTTCCCTGACTTTC-3’ (forward) 
5’-AGCGGAGGTGCCTGTGC-3’ (reverse) 
59 198
VEGF 5’-CTGCTCTCTTGGGTGCACTGG-3’ (forward) 
5’-CACCGCCTTGGCTTGTCACAT-3’ (reverse) 
59 563
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Gen Sequence Annea-
ling 
(°C) 
Size 
(bp)
IP-10/ 
CXCL10 
5’-TCCCTCTCGCAAGGACGGTC-3’ (forward)  
5’-GTGTGTGCGTGGCTTCACTC-3’ (reverse) 
59 256
VCAM 5’-TGACAAGTCCCCATCGTTGA-3’ (forward) 
5’-ACCTCGCGACGGCATAATT-3’ (reverse) 
59 110
c-Myc 5’-AGCTGTTTGAAGGCTGGATT-3’ (forward)  
5’-CCGCAACATAGGATGGAGAG-3’ (reverse) 
59 372
Cyclin D2 5’-ATTTCAAGTGCGTGCAGAAG-3’ (forward) 
5’-ACACTTCTGTTCCTCACAGACCT-3’ (reverse) 
64.5 121
 
Table 17. RT-PCR protocols. 
Standard RT-PCR protocol 95°C, 1.5 min 
(95°C, 30 sec, 59°C, 30 sec, 72°C, 30 sec) 40 x 
(50-95°C, 30 sec, 0.5°C) 90 x 
10°C, hold 
Adaptation 56°C 56°C, 35 sec 
Adaptation 60°C 60°C, 30 sec 
Adaptation 62°C 62°C, 50 sec 
Adaptation 64.5°C 64.5°C, 40 sec 
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2.17 Immunohistochemistry 
2.17.1 Immunohistochemistry and immunofluorescence of frozen tumour   
tissue sections  
Immunohistochemistry (IHC) is used to identify specific antigens in tissues  
[303]. Immunofluorescence (IF) of tissues is methodologically identical to this 
technique but uses a different detection and imaging system [304]. 
Tumours obtained from mice at day 18 after tumour cell injection were directly 
embedded in tissue freezing medium (Tissue tec, Jung/Leica), snap frozen in 
liquid nitrogen for cryosectioning, and stored at -80°C. Specimens were cut in  
10 µm sections. To fix sections, slides were covered with acetone or 1:1 
acetone/methanol for 10 min at -20°C. After air drying the slides for 30 min, 
slides were treated with 0.3% (v/v) H2O2 in methanol for 15 min to eliminate 
endogenous peroxidase activity. After washing the slides three times with PBST 
(0.1% (v/v) Tween 20 in PBS), the tissue sections were encircled on the glass 
slide with a Pap pen (water repellant wax, DakoCytomation), creating a 
boundary that prevented mixture of reagents. All further incubation procedures 
were performed in a humidified staining chamber. After blocking non-specific 
binding sites with specific sera for 30-60 min, the sections were incubated with 
diluted primary antibody in PBST for 60 min at RT or over night at 4°C. Isotype-
matched IgG served as negative control in all stainings. The slides were 
washed three times in PBST for 10 min and the sections were stained with the 
secondary biotinylated antibody in PBST for 30 min at RT. After another 
washing step, the slides were incubated with a horseradish peroxidase (HRPO)-
conjugated avidin-biotin complex (ABC, VectorLab/Linaris) for 30 min at RT 
[305]. 3-Amino-9-ethyl carbazole (AEC, VectorLab/Linaris) or 3,3′-diamino-
benzidine (DAB, VectorLab/ Linaris) substrate solution was added to the slides 
after washing and specimens were incubated for 5 to 30 min till proper color 
development occured. AEC gives a bright red precipitate whereas DAB results 
in an intense brown precipitate. The slides were counterstained for 30 sec to     
2 min with hematoxylin for nuclei staining (Chem Mate, DakoCytomation) and 
mounted with aquatex (Merck).  
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For immunofluorescence labeling the secondary antibody was fluorescently 
tagged (Cy3) and directed against the primary antibody host species. Sections 
were counterstained with Yopro1 for nuclei staining and mounted with 
moviol/DABCO (33% (v/v) glycerin, 13% (w/v) moviol, 130 mM Tris, 50 mg/ml 
DABCO in dH2O).  
Serial sections of eight representative tumours of Th1 cell treated and control 
mice from day 18 after tumour cell injection were stained (Table 18). Digital 
images at the magnification indicated were obtained using an Axiovert 200 
Fluorescence microscope. 
 
Table 18. Protocol for immunohistochemistry. 
Antigen Step Characteristics 
CD4 
(surface 
marker) 
Fixation 
Blocking 
Primary antibody 
Substrate 
1:1 acetone/methanol, 10 min, -20°C 
not required 
1:40 dilution in PBST, 1 h, RT 
DAB, 8-10 min 
PECAM-1 
(platelet 
endothelial 
cell adhesion 
molecule) 
Fixation 
Blocking 
Primary antibody 
Secondary antibody 
Nuclei staining  
acetone, 10 min, -20°C 
1:20 donkey-serum in PBS, 1 h, RT 
undiluted, 1 h, RT 
1:500 donkey α-rat Cy3 in PBST 
1:2000 Yopro1 in PBST, 5 min, RT 
VEGFR-2 
(endothelial 
receptor 
tyrosine 
kinase) 
Fixation 
Blocking 
Primary antibody 
Secondary antibody 
Nuclei staining  
acetone, 10 min, -20°C 
1:20 donkey-serum in PBS, 1 h, RT 
undiluted, 1 h, RT 
1:500 donkey α-rat Cy3 in PBST 
1:2000 Yopro1 in PBST, 5 min, RT 
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For routine histology analysis, cryosections of the same eight representative 
tumours of Th1 cell treated and control mice from day 18 after tumour cell 
injection were stained automatically with hematoxylin/eosin (H&E) using the 
Varistain 24-4, Promounter RCM90, and an automatic coverslipping machine. 
By the alkaline hematoxylin, all basophilic cell and tissue structures, particularly 
the chromatin of cell nuclei, are stained blue. The acidic eosin stains acidophilic 
cell components such as cytoplasma and most intracellularly substances red. 
2.17.2 Toluidin blue staining of mast cells 
Frozen tumour sections of the same eight representative Th1 cell treated and 
control mice from day 18 after tumour cell injection were used for the 
proteoglycan staining with toluidine blue to detect mast cells. Therefore, 
sections were fixed in acetone for 10 min at RT and air dried. Staining of 
specimen was carried out in toluidine blue solution (0.1% (w/v) toluidine blue in 
dH2O) for 10 min at RT. Sections were washed in dH2O short-time, air dried, 
and mounted with Entellan (Merck). 
2.17.3 Ki-67 staining of fixed paraffin-embedded tumour sections  
Tumours obtained from mice at day 18 after tumour cell injection were fixed in    
1% (w/v) paraformaldehyde (PFA). Using the Hypercenter XP, specimen were 
washed, dehydrated through a graded ethanol series, and impregnated in 
paraffin wax. With the Tes99 instrument tumours were cast into blocks. 
Specimen of four representative tumours of Th1 cell treated and control mice 
were cut into 7 µm sections and dried over night at 60°C for better adherence to 
the slide. For immunohistochemistry, slides were deparaffinised with the          
24 stainer. For unmasking Ki-67, a cell proliferation-associated nuclear antigen, 
specimen were heated in target-retrieval solution (DakoCytomation) in a 
steamer for 15 min. After washing the slides in PBST, immunohistochemistry 
was performed as mentioned above (2.17.1), starting with peroxidase blocking. 
Ki-67 primary antibody was diluted (1:25) in antibody diluent (DakoCytomation) 
and sections were incubated for 1 h at RT. DAB was used as substrate. 
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2.18 Electron microscopy of tumours 
Tumour samples for electron microscopy (EM) analysis were cut into small 
pieces and immediately fixed by immersion in 1.5% (w/v) glutaraldehyde in    
0.1 M cacodylate buffer with 5% (w/v) sucrose for 2-4 h. After washing with    
0.1 M cacodylate buffer with 7.5% (w/v) sucrose, specimen were given to     
Prof. Dr. Wolburg (Institute of Pathology, Tübingen) for further treatment, 
photographing, and analysis. Briefly, specimen were postfixed in cacodylate 
buffer containing 1% (w/v) OsO4 for 1 h and dehydrated in ascending series of 
ethanol and propyleneoxide. For contrast enhancement they were bloc-stained 
in uranyl-acetate in 70% ethanol for 4 h and flat-embedded in Araldite (Serva). 
Using an ultramicrotome (Ultracut R, Leica) semi- (1 µm) and ultrathin sections 
(50 nm) were cut. Ultrathin sections were stained with lead citrate, mounted on 
copper grids, and finally analysed with a Zeiss EM 10 Electron microscope. 
2.19 Protein chemical methods 
2.19.1 Cell lysis and Wessel-Fluegge precipitation 
For protein analysis HUVEC (p3, p4, p5) were seeded at 2 x 105 cells/well in a 
6-well plate, grown to 80% confluency, and medium was changed with the 
appropriate concentrations of DMF and/or NAC; MCDB131 medium alone 
served as negative control. The next day cells were serum starved (0.3% (v/v) 
FCS in MCDB131) for 7 h and stimulated by adding 1% (v/v) ECGS, 40 µg/ml 
heparin, and 20 ng/ml VEGF. Cells were scraped directly into 80 µl 6 x SDS 
sample buffer with disruption of cell membrans by freeze-thawing in liquid 
nitrogen (3 times) or into 150 µl lysis buffer per well (Table 19).  
 
Table 19. Treatment of cells for protein preparation. 
Protein Stimulation Scraping in 
p38 7 min 80 µl 6 x SDS sample buffer 
p44/42 7 min 80 µl 6 x SDS sample buffer 
mTor 30 min 150 µl lysis buffer 
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After cell lysis, proteins were precipitated according to Wessel-Fluegge [306]. 
Briefly, the cell suspension was vortexed with 600 µl methanol and 150 µl 
chloroform. After adding 450 µl dH2O the cell suspension was vortexed again, 
centrifuged (13000 rpm, 1 min), and the upper organic phase was removed. 
Another 450 µl methanol were added, cells were vortexed, and centrifuged 
(13000 rpm, 2 min). After removal of the supernatant, the pellet was air dried 
and resuspended in 50-80 µl 6 x SDS sample buffer for further use. 
Spectrophotometric quantitation of the amount of protein was performed using 
the Bradford method (BioRad). 
To prevent proteolysis and also avoid heating artifacts specific protease 
inhibitors were used during protein isolation. 
 
Table 20. Buffers used for protein sample preparation. 
Lysis buffer 1 mM EDTA 
0.005% (v/v) Tween 20 
0.5% (v/v) Triton X 
5 mM NaF 
6 M urea 
Before use: 
25 µg/ml leupeptin 
25 µg/ml pepstatin 
100 µM PMSF 
3 µg/ml aprotinin 
2 mM sodium orthovanadate 
6 x SDS sample buffer (pH 6.8) 300 mM Tris 
45% (v/v) glycerol  
300 mM SDS  
48 mM dithiothreitol (DTT)  
0.15% (w/v) bromophenolblue  
dH2O 
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2.19.2 Spectrophotometric quantitation of proteins (Bradford) 
Quantitation of the amount of sample protein contained in solution was 
accomplished using a colorimetric method, the Bradford method [307]. This 
method is based upon binding of the dye Coomassie brilliant blue G-250 to an 
unknown protein. Quantification is possible if this binding is compared to that of 
different amounts of a standard protein, usually BSA. This assay can be used to 
quantitate solutions with protein concentrations of 125 to 1000 µg/ml and was 
performed according to the manufacturer’s instruction manual (BioRad). 
2.19.3 Electrophoretic separation of proteins  
For separation of proteins, discontinuous sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) was performed. Proteins were 
denatured by heating in the presence of SDS and 2-mercaptoethanol or 
dithiothreitol (DTT) to reduce disulfide bonds. Proteins bind SDS in a constant 
weight ratio and migrate in the polyacrylamide gel according to size in response 
to an electrical field. Addition of ammonium persulfate initiates the 
polymerisation of monomeric acrylamide, leading to polyacrylamide gels. 
N,N,N’,N’-Tetramethyl-ethane-1,2-diamine (TEMED) which catalyses the 
formation of free radicals from ammonium persulfate accelerates this reaction 
(according to [308]).  
Electrophoresis was performed using mini gels (Protean II) and a discontinuous 
buffer system [309]. The separating gel was poured between a glass-plate 
sandwich, consisting of two clean glass plates and two 0.75-mm spacers, and 
covered with ethanol to form a flat interface. The desired percentage of 
acrylamide in the separating gel depends on the molecular size of the proteins 
being separated (Table 21/22).  
Table 21. SDS gel concentrations used for specific proteins. 
protein acrylamide concentration and size of protein 
p38 12.5%, 38 kDa 
p44/42 15-18%, 42/44 kDa 
mTor 7.5%, 180 kDa 
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Table 22. Molecular size of proteins which can be separated by SDS-PAGE [310].  
Acrylamide (%) Size of fragments 
separated (bp) 
Size of fragments 
separated (kDa) 
5.0 100 to 500 26 to 130 
8.0 60 to 400 16 to 105 
12.0 50 to 200 13 to 52 
20.0 5 to 100 2 to 26 
 
After polymerisation the ethanol layer was removed, the stacking gel was 
poured, and a 0.75-mm Teflon comb was inserted into the layer of stacking gel 
solution. After polymerisation the glass-plate sandwich was secured in an 
electrophoresis apparatus and the electrophoresis tank was filled with running 
buffer. After sample proteins were boiled in 6 x SDS sample buffer (5 min at 
95°C), 25 µl of the protein solutions and 5-10 µl of specific molecular markers 
(visible and fluorescent) were applied to gel lanes. Gels were run at 90-120 V 
for 1-2 h until the desired resolution was obtained. 
 
Table 23. Preparation of separating and stacking gel. 
 
Separating gel 
Stacking 
gel 
 Final acrylamide concentration (%) 
Stock solution 7.5 12.5 15 3.9 
30% acrylamide/0.8% bisacrylamide (ml) 4.30 7.10 10.00 1.20 
separating/stacking gel buffer (ml) 4.25 4.25 5.20 2.25 
H2O (ml) 8.20 5.40 4.60 5.30 
10% (w/v) ammonium persulfate (µl) 150 150 200 100 
TEMED (µl) 8.5 8.5 8.5 15.0 
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Table 24. Buffers used for SDS gel electrophoresis. 
Separating gel buffer (pH 8.8) 1.5 M Tris 
15 mM SDS 
dH2O 
Stacking gel buffer (pH 6.8) 0.5 M Tris 
15 mM SDS 
dH2O 
Running buffer 24.8 mM Tris 
3.5 mM SDS 
0.2 M glycine 
dH2O 
 
2.19.4 Electroblotting and Western blot analysis 
Proteins separated by SDS-PAGE were electroblotted onto a polyvinylidene 
difluoride (PVDF) membrane (Hybond P, pore size 0.2 µm, Amersham 
Biosciences) in a semidry transfer unit. Therefore, one sheet of a semidry 
buffer-soaked Whatman filter paper (Biometra) was placed on the anode, 
followed by the methanol-equilibrated membrane, the gel, and one more sheet 
of the semidry buffer-soaked filter paper. After removing air bubbles between 
membrane and filter paper, transfer of proteins was obtained by applying a 
maximum current of 0.8 mA per cm2 of gel area according to the manufacturer’s 
instructions (Amersham Biosciences) for 60-90 min (Table 25).  
 
Table 25. Blotting time of specific proteins. 
protein Blotting time  
p38 1 h 
p44/42 1 h 
mTor 1.5 h 
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Subsequently, transferred proteins that are bound to the surface of the 
membran can be analysed by immunoblotting (Western blotting) [311]. To 
identify specific antigens, the non-specific binding sites on the membrane were 
blocked by immersing the membrane in a PBST solution containing 5% (w/v) 
nonfat dry milk for at least 1 h at RT or over night at 4°C. Then, the membrane 
was stained with a specific primary antibody directed against specific antigens 
over night at 4°C in 5% (w/v) nonfat dry milk or BSA in PBST. The blot was 
washed three times with PBST. The secondary anti-IgG antibody was tagged 
with alkaline phosphatase enzyme (Amersham) and remained on the 
membrane for 1 h at RT. After washing the membrane again, the specific 
proteins were detected using the fluorescent substrate ECF (Amersham). 
Fluorescence scanning at 570 nm was performed using a phosphoimager. The 
image was recorded and the protein concentration was quantitated by 
densitometry using Image Quant. 
 
Table 26. Buffers used for immunoblotting and western blot analysis.  
Semidry buffer 48 mM Tris  
39 mM glycine 
1.3 mM SDS  
20% (v/v) methanol  
dH2O 
PBS 2.6 mM KCl 
1.5 mM KH2PO4  
136.9 mM NaCl 
10.1 mM Na2HPO4 
dH2O  
PBST 0.1% (v/v) Tween 20  
PBS  
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2.19.5 Enzyme-linked immunosorbent assay  
With the Enzyme-linked immunosorbent assay (ELISA) every protein of interest 
can be detected in cell lysates depending on the used antibody. The ELISA is 
also used to measure the accumulation of a distinct cytokine secreted into a cell 
culture supernatant over an incubation period of 12-48 h. For detection of 
phosho-p38 in cell lysates, IFN-γ, and IL-4 in supernatants sandwich ELISAs 
were performed according to the manufacturers’ instructions (R&D Systems, BD 
Biosciences). A 96-well microplate was coated with a capture antibody specific 
for the proteins to be detected. After blocking unspecific binding sites, a 
standard of the target protein and the samples were loaded in duplicates onto 
the plate. Specific proteins were detected with a biotinylated detection antibody, 
following Streptavidin-HRP, determination of the optical density of each well 
using a microplate reader set to 450 nm, and subsequent calculation of the 
protein content. 
HUVEC (p3, p4, p5) were grown over night with appropriate concentrations of 
DMF. Cells were serum starved (1% (v/v) FCS in MCDB131) for 6 h. After 
stimulation of cells with 1% (v/v) ECGS, 40 µg/ml heparin, and 20 ng/ml VEGF 
for 7 min cells were scraped directly into 100 µl cell lysis buffer for analysis of 
the phospho-p38 content. 
For IFN-γ and IL-4 ELISA LN T cells (0.1 x 106 cells/well) were stimulated with   
1) APC alone (0.5 x 106 cells/well), 2) APC and EpCAM (1 µg/ml), 3) medium as 
negative control, and supernatants were collected after 48 h for further analysis. 
2.20 In vitro and in vivo angiogenesis assays 
2.20.1 Proliferation assay through BrdU incorporation  
There are numerous assays for measuring cell proliferation, for example the 
thymidine incorporation assay and the 5-bromo-2’-deoxyuridine (BrdU) 
incorporation assay. The exposure of cells to the pyrimidine analogue BrdU 
causes proliferating cells to incorporate BrdU into their DNA. So, measuring the 
BrdU uptake directly correlates the amount of DNA synthesis and the number of 
cells in culture. 
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HUVEC or HLMEC were seeded at 7500 cells/well in a 96-well plate in 
triplicates. After 8 h, cells were stimulated by adding 1% (v/v) ECGS, 40 µg/ml 
heparin, and 20 ng/ml VEGF, or 100 ng/ml VEGF alone. In combination with the 
stimulating mixture the appropriate concentrations of DMF and/or NAC or 
glutathione monoethyl-glycyl ester (GSH-OEt) were added. MCDB131 medium 
containing 5% (v/v) FCS for HUVEC, or 2% (v/v) FCS for HLMEC served as 
negative control. After 12 h stimulation, BrdU was added and after 16 h of 
incubation the proliferation was measured by BrdU incorporation according to 
manufacturer’s instructions (Amersham Biosciences).  
2.20.2 Migration assay - Scratch-wound assay 
Several assays can be used to determine the migratory response of EC to 
angiogenic factors, for example modified Boyden chamber experiments. Here, 
we used a different approach based on the idea that EC migration represents a 
pivotal event of wound healing in vivo [312].  
Therefore, HUVEC were grown to confluency. A migration gap was created by 
introducing a scratch on the monolayer using a sterile pipette tip. For stimulation 
of cells 1% (v/v) ECGS, 40 µg/ml heparin, and 20 ng/ml VEGF alone or in 
combination with the appropriate concentrations of DMF were added. 
MCDB131 medium with 5% (v/v) FCS served as negative control. After an 
incubation period of 9 h, cells were fixed with 1% (w/v) PFA and stained with 
crystal violet (0.5% (w/v) crystal violet (Roth) and 20% (v/v) methanol in PBS).  
After growing HMLEC to confluency they were serum starved (5% (v/v) FCS in 
MCDB131) for 5 h before introducing a scratch. Stimulation of HMLEC was 
identical to HUVEC but HMLEC were grown over night and then fixed.  
Cells in the migration gap were counted microscopically in nine different areas 
per plate on the basis of phase-contrast micrographs at 0 h and at 9 h for 
HUVEC, and at 16 h for HMLEC. 
2.20.3 Sprout formation assay 
This angiogenesis assay allows three-dimensional neovessel formation in vitro. 
It was performed as described elsewhere [313]. Briefly, HLMEC were seeded 
on cytodex-3 microcarrier beads (SigmaAldrich) and embedded into a three-
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dimensional fibrin gel (SigmaAldrich) containing 20 ng/ml VEGF either alone or 
in combination with DMF and/or NAC or GSH-OEt in triplicates. Fibrin gels 
without growth factors served as a negative control. Cross-linking of fibrinogen 
and polymerisation of fibrin was started by adding 0.65 U/ml thrombin 
(SigmaAldrich). Thereafter, gels were incubated in MCDB131 containing the 
appropriate concentrations of VEGF, DMF, and/or NAC, or GSH-OEt, 5% (v/v) 
FCS, 5% (v/v) human serum, and 200 U/ml trasylol (Bayer). After 24 h, the gel 
was fixed in 1% (w/v) PFA and the number of sprouts per 50 beads was 
counted microscopically.  
2.20.4 Chick choreoallantoic membrane assay 
Among the in vivo systems the chick choreoallantoic membrane (CAM) assay is 
a technically simple and inexpensive approach to study angiogenesis and 
demonstrates a functional assay to test pro- and antiangiogenic factors. The 
CAM assays were performed in ovo as described elsewhere [314, 315]. Briefly, 
after aspiration of 2 ml of egg white of fertilized hen's eggs to minimize adhesion 
of the shell membrane, a window was cut into the eggshell on embryonic day 3. 
The eggs were resealed with a tape and further incubated at 37°C in humidified 
air until day 7. Whatman filters containing the appropriate DMF concentrations 
were placed onto E7 CAMs and incubated for three days. Filters with DMSO 
alone served as a negative control. For documentation, a stereo microscope 
with camera adaptor was used to take photographs. 
2.21 Statistical analysis 
Differences between experimental groups were determined with an unpaired 
Mann-Whitney test using SPSS software (Chicago, Illinois). P values of < 0.05 
were considered statistically significant. 
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3 Results 
3.1 The effects of tumour antigen-reactive Th1 cells on tumour 
growth and angiogenesis 
3.1.1 Adoptive transfer of tumour-reactive Th1 cells leads to an 
inhibition of tumour growth in vivo 
It was previously shown that it is possible to generate IFN-γ producing Th1 cells 
against the tumour-associated antigen (TAA) EpCAM which is differentially 
expressed on human gastrointestinal tumours including colon cancer [97, 316], 
from immunised mice ex vivo. Generation of such EpCAM-reactive INF-γ 
producing Th1 cells required priming of IL4-/- BALB/c mice, and subsequent in 
vitro stimulation and expansion of the CD4+ T cells with EpCAM protein, CpG-
oligodeoxynucleotides (ODN), APC, and IL-2 [99]. Adoptive transfer of these 
EpCAM-reactive Th1 cells provided solid protection against intravenously 
injected EpCAM-expressing tumours whereas Th2 cells failed (R. Mocikat,      
H. Braumüller, unpublished data). 
To investigate the therapeutic mechanisms underlying the Th1 cell-mediated 
immunotherapy, we first adapted the therapy to a subcutaneous tumour model. 
We injected murine colon carcinoma cells (1.5 x 106) that stably expressed 
EpCAM (CT26-EpCAM) into the right and left flank of syngeneic BALB/c mice 
on day 0 (Fig. 5). After three days, mice were irradiated to induce a mild 
inflammatory response and hence, to amplify the capacity of T cells to infiltrate 
the tumour [171]. On day 4, EpCAM-reactive Th1 cells (5 x 106) were injected 
intraperitoneally into the tumour bearing mice. The control group received PBS 
(Fig. 5).  
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Figure 5. Schematic outline of the experimental strategy. 
For generation of EpCAM-reactive Th1 cells, CD4+ T cells from immunised    
IL4-/- BALB/c mice were stimulated with EpCAM protein in vitro in the presence 
of the Toll-like receptor (TLR)-9 ligand CpG1668 to enhance IL-12 production 
by APC [99, 317]. Cells were expanded for 14 days in medium containing IL-2 
(50 U/ml) and then characterised by flow cytometry for representative Th1 and 
Th2 cytokines before adoptive transfer. The majority of cells was CD4 positive 
and about 30% of the CD4+ T cell population produced IFN-γ (Fig. 6A). No IL-4 
and only few IL-10 expressing cells were detectable (Fig. 6A) confirming the 
Th1 phenotype of the T cells. Th1 cells which were gained from lymphnodes of 
immunised IL4-/- BALB/c mice and were stimulated and expanded for 14 days in 
vitro, were used for an IFN-γ ELISA showing the reactivity of Th1 cells against 
EpCAM protein (Fig. 6B). 
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Figure 6. Characterisation of generated T cells. A, Flow cytometric analysis of 
generated T cells. Cultured cells were stimulated with PMA/Ionomycin, stained with 
surface anti-CD4 and intracellularly with anti-IFN-γ, anti-IL-4, or anti-IL-10, respectively, 
showing the Th1 phenotype of EpCAM-primed T cells. Representative dot plots are 
shown. Numbers indicate the percentage of cells in the particular fluorescence window. 
B, Representative IFN-γ ELISA of lymphnode-derived EpCAM-primed Th1 cells, 
showing the reactivity of Th1 cells against EpCAM protein. 
To determine the impact of such CD4+ Th1 cells on MHC-class II negative 
CT26-EpCAM tumours, we first measured tumour growth with a sliding calliper 
on days 10, 13, and 17 after tumour cell injection and calculated the tumour 
area. Until day 10, the Th1 cell treated and the PBS treated group showed 
similar tumour growth dynamics. From day 13 on, the group that had received 
the adoptive Th1 cell therapy showed a significant inhibition of tumour growth 
(Fig. 7).  
 
Figure 7. Determination of the therapeutic effect of adoptively transferred tumour-
reactive Th1 cells on tumour growth. Tumours from Th1 cell treated (d10: n = 34; d17: 
n = 34; d13: n = 24) and PBS treated (d10: n = 22; d17: n = 22; d13: n = 12) mice were 
measured with a sliding calliper and tumour area was calculated as product of 
perpendicular tumour diameters (*: p < 0.05). Data revealed an inhibitory effect of the 
adoptive Th1 cell transfer on tumour growth from day 13 on. Error bars denote 
standard error of the mean (SEM). 
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To analyse the mechanisms underlying this inhibitory effect, tumours were 
harvested on days 10, 11, 13 and 18 after tumour cell injection. First, we 
determined the tumour weight and secondly, the intra-tumoural cytokine 
patterns were analysed. On day 18, we found a 40-84% reduction of tumour 
weight in the Th1 cell treated mice compared to control tumours (Fig. 8A). In 
contrast, on day 11, there was only a slight, non-significant decrease of tumour 
weight in the Th1 cell treated group (Fig. 8A). To evaluate the onset of the 
therapy in more detail, the tumour weight was determined on day 10 and day 13 
after tumour cell injection in an independent experiment. We found a prominent 
decrease of tumour weight in Th1 cell treated mice compared to PBS treated 
mice on day 13 (Fig. 8B). On day 10, we detected a not significant increase of 
tumour weight in Th1 cell treated mice compared to PBS treated mice (Fig. 8B). 
These results indicate that the growth inhibition due to the therapy started 
between day 10 and day 13. 
 
 
Figure 8. Adoptive transfer of tumour-reactive Th1 cells leads to inhibition of tumour 
growth. A, The inhibition of tumour growth is shown by analysing the tumour weight of 
Th1 cell and PBS treated mice on day 11 (n = 22) and day 18 (n = 34) after tumour cell 
injection (*: p < 0.05). B, The difference in tumour weight on day 10 (n = 10) and day 13 
(n = 10) after tumour cell injection is shown from one experiment out of three.              
∆: reduction or increase of tumour weight in Th1 cell treated mice compared to PBS 
treated mice. 
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To ensure that the tumour growth inhibition was caused by the adoptive transfer 
of EpCAM-reactive Th1 cells, CT26-EpCAM tumour bearing mice were treated 
with ovalbumin (OVA)-specific Th1 cells. Therefore, CD4+ T cells were isolated 
from transgenic DO11.10 mice which express the TCR specific for the chicken 
OVA peptide. Cells were stimulated with OVA peptide and APC in vitro and the 
Th1 cell phenotype was confirmed by flow cytometry (Fig. 9A). The adoptive 
transfer of OVA-Th1 cells did not inhibit tumour growth (Fig. 9B), demonstrating 
that specific, tumour-antigen reactive Th1 cells were required for the inhibition 
of CT26-EpCAM tumour growth in vivo. 
 
 
Figure 9. Adoptive transfer of OVA-primed Th1 cells shows no inhibition of tumour 
growth. A, Flow cytometric analysis of generated T cells. Cultured OVA-primed T cells 
were stimulated with PMA/Ionomycin, stained with surface anti-KJ1-26 (specific for the 
TCR expressed on DO11.10 mice) and intracellularly with anti-IFN-γ, anti-IL-4, or    
anti-IL-10, respectively, for Th1 and Th2 cytokines showing the Th1 phenotype of the 
OVA-primed cells. Representative dot plots are shown. Numbers indicate the 
percentage of cells in the particular fluorescence window. B, OVA-primed Th1 cells 
were injected in CT26-EpCAM tumour bearing mice. No difference in tumour weight   
(n = 12) was observed. ∆: increase of tumour weight in the Th1 cell treated group 
compared to the PBS treated group. 
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3.1.2 Upregulation of Th1 associated cytokines and angiogenesis 
regulatory genes after adoptive Th1 cell transfer 
To analyse the mechanisms by which the adoptive transfer of tumour-antigen 
reactive Th1 cells led to the profound inhibition of tumour growth we examined 
the intra-tumoural gene expression profile at different points in time. Therefore, 
four major groups of genes were investigated that may interfere with tumour 
growth at different levels: 1) genes of the Th1/Th17 cytokine family, 2) genes 
associated with innate inflammation, 3) genes associated with angiogenesis 
and 4) genes associated with the cell cycle.  
Since we injected IFN-γ producing Th1 cells for therapy, the first group of genes 
analysed were Th1/Th17 associated genes such as IFN-γ [157], IL-12, IL-23,  
IL-27 [199, 208], and IL-6. Moreover, IFN-γ inducible genes such as                
IP-10/CXCL10, Mig/CXCL9 [192, 193] and their receptor CXCR3 (CD183) 
which is preferentially expressed on Th1 cells but also on NK cells, DC, and 
macrophages were analysed [318, 319].  
The second group reflected genes which are associated with innate 
inflammation. The adhesion molecules ICAM-1 and VCAM may contribute to 
the therapeutic effect as they are upregulated in EC during inflammation and 
are required for rolling and adhesion of leukocytes to support their infiltration 
[320].  
Tumour growth depends on blood vessel formation. Therefore, genes 
associated with angiogenesis such as VEGF, PIGF, Ang-1, and Ang-2 were 
analysed in the third group [19, 46, 77, 321]. Moreover, IL-12, IL-27,               
IP-10/CXCL10, and Mig/CXCL9 are cytokines/chemokines that exhibit 
antiangiogenic properties [216, 234].  
Markers associated with cell proliferation or growth arrest such as the oncogene 
c-Myc and its target gene Cyclin D2, a protein involved in cell cycle progression, 
were analysed in the last group [322-325].  
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Tumours were harvested at different points in time after tumour cell injection 
and total RNA was extracted from single tumours for PCR and quantitative real-
time PCR analysis. First, we analysed different candidates of house keeping 
genes by semiquantitative PCR and found that hypoxanthine-guanine 
phosphoribosyl-transferase (HPRT) in contrast to glyceralehyde-3-phosphate 
dehydrogenase (GAPDH) and Aldolase was not regulated in our tumour model. 
Therefore, HPRT served as house keeping gene in our system (Fig. 10).  
 
 
Figure 10. Analysis of different house keeping genes by semiquantitative PCR. On day 
18 after tumour cell injection representative tumours (n = 4) from Th1 cell treated and 
PBS treated mice were analysed for different house keeping genes by PCR and gel 
images were densitometrically evaluated. HPRT (cycles: 20) expression in tumours 
compared to GAPDH (cycles: 18) and Aldolase (cycles: 20) showed no difference 
between Th1 cell treated and PBS treated mice by densitometry, pointing out that 
HPRT is not regulated in our model system. 
Real-time PCR data showed that Th1-associated and immunoregulatory genes 
were upregulated in Th1 cell treated tumours from day 11 onwards, peaking on 
day 13 (Fig. 11A). The most pronounced upregulation was found for IL-23/p19 
and IL-12/p35 on day 13 after tumour cell injection in Th1 cell treated tumours 
(Fig. 11A) whereas the expression of the corresponding subunit p40 was only 
slightly changed (Fig. 11B). Elevated levels of IFN-γ were found and the therapy 
also increased levels of ICAM-1, IL-6, and IL-27/Ebi3 (Fig. 11A) whereas the 
subunit IL-27/p28 remained almost unchanged (Fig. 11B). Surprisingly, we also 
found a very late downregulation of VCAM in Th1 cell treated tumours at day 18 
after tumour cell injection (Fig. 11B). In contrast, the therapy did not influence 
the expression of the angiogenesis associated genes VEGF and IP-10/CXCL10 
(Fig. 11B). Moreover, semiquantitative PCR data showed that the expression of 
Ang-1, Ang-2, PIGF, Mig/CXCL9, and CXCR3 was also similar in both groups 
(Fig. 11C). The expression of neither c-Myc nor Cyclin D2 was affected by the 
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therapy at any of the times analysed (Fig. 11B). In summary, these data 
suggest an important role for cytokines of the IL-6 family in tumour growth 
inhibition after Th1 cell transfer.  
 
Figure 11. Gene expression analysis of tumours by PCR at different points in time.        
A, B, In real-time PCR analysis multiplex reactions were run in triplicates and samples 
were normalized to the house keeping gene HPRT. Relative expression of genes of 
interest is represented as fold differences of the mean of Th1 cell treated mice (d10:    
n = 10; d11: n = 10; d13: n = 10; d18: n = 9) over PBS controls (d10: n = 10; d11:         
n = 10; d13: n = 8; d18: n = 9) with highest levels on day 13 (*: p < 0.05). B, Genes 
found only slightly or not regulated by real-time PCR analysis. Fold differences of the 
mean of Th1 cell treated over PBS controls are shown (n.a.: not analysed).                 
C, Semiquantitative PCR data showed that the expression of analysed genes was 
similar in both groups.  
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3.1.3 Prevention of Th1 cell suicide with anti-IFN-γ antibody further 
promotes tumour growth inhibition by Th1 cells 
The upregulation of IFN-γ and the IFN-γ inducible cytokine IL-12 in tumours 
after Th1 cell transfer suggests that the therapeutic effects might be IFN-γ 
dependent. To block the IFN-γ mediated suicide of Th1 cells [326], we treated 
tumour bearing mice with 500 µg anti-IFN-γ monoclonoal antibody (mAb) one 
day before adoptive transfer of EpCAM-reactive Th1 cells. In agreement with 
the suicide hypothesis [326], we observed an even stronger reduction of tumour 
growth in mice receiving the combined injection of Th1 cells and anti-IFN-γ mAb 
(Fig. 12A) compared to mice either treated with Th1 cells alone or with PBS on 
day 17 after tumour cell injection. Reduced tumour growth was associated with 
an even stronger upregulation of IFN-γ in tumours of mice with combined Th1 
cell and anti-IFN-γ therapy as compared to mice with PBS treatment (Fig. 12B). 
Tumours treated with Th1 cells alone also showed an upregulation of IFN-γ 
compared to control tumours but to a much lesser extent than the Th1 cell and 
anti-IFN-γ treated group. The other cytokines remained comparable between 
the Th1 cell and anti-IFN-γ mAb treated group and the group treated with Th1 
cells alone (Fig. 12B). 
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Figure 12. Combined Th1 cell and anti-IFN-γ treatment leads to further reduction of 
tumour growth. A, On day 3, mice were irradiated, treated with 500 µg  anti-IFN-γ 
antibody, and on day 4, EpCAM-reactive Th1 cells were injected. Tumour weight of 
PBS treated (n = 18), Th1 cell treated (n = 10), and combined treated (n = 8) mice was 
analysed on day 17. ∆: Reduction of tumour weight of Th1 cell treated mice compared 
to PBS controls (*: p < 0.05). B, Real-time PCR data of tumours. Multiplex reactions 
were run in triplicates and samples were normalized to the house keeping gene HPRT. 
Relative expression of genes of interest is represented as fold differences of the mean 
of Th1 cell treated mice (n = 7) or combined treated mice (anti-IFN-γ, n = 6) over PBS 
controls (n = 14) on day 17 after tumour cell injection. A strong upregulation of IFN-γ 
was found in tumours treated with both Th1 cells and anti-IFN-γ mAb (*: p < 0.05). 
Since we found inflammatory cytokines upregulated in tumours of Th1 cell 
treated mice, we further investigated the differentiation of the developing T cells 
into either Th1 or Th17 cells in vitro. Th17 cells can regulate tissue inflammation 
through production of IL-17, a pro-inflammatory cytokine [239, 242]. As 
expected from the priming protocol using CpG-ODN [327, 328], we found cells 
expressing IL-17 in the EpCAM-reactive Th1 cell culture. Yet, the IFN-γ 
producing T cells repeatedly exceeded the number of IL-17 producing cells 
about 3 fold (Fig. 13).  
 
Figure 13. Further analysis of the Th1 cell population used for therapy. In vitro flow 
cytometric analysis of CD4+ T cells, stimulated with PMA/Ionomycin, stained with 
surface anti-CD4 and intracellularly with anti-IL-17 or anti-IFN-γ, respectively, revealing 
IL-17 expressing cells in the EpCAM-reactive Th1 cell culture. Representative dot plots 
are shown.  
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Next, we investigated whether IL-17 expression in tumours might be relevant for 
therapy. Quantitative real-time PCR revealed significantly upregulated levels of 
IL-17 in tumours of Th1 cell treated mice compared to PBS treated mice on     
day 13 and day 18 after tumour cell injection (Fig. 14A), suggesting that IL-17 
producing cells might be involved in the therapy. However, on day 17, the IL-17 
expression was reduced in tumours of mice receiving the combined injection of 
Th1 cells and anti-IFN-γ mAb compared to tumours of mice treated with Th1 
cells alone (Fig. 14B). This furthermore supports the suicide hypothesis [326] 
and argues in favour of preferential expansion of Th1 cells.  
 
 
Figure 14. Real-time PCR data of tumours. A, IL-17 expression in tumours of Th1 cell 
treated (d10: n = 10; d13: n = 8; d18: n = 9) and control mice (d10: n = 10; d13: n = 7; 
d18: n = 12) on days 10, 13, and 18 showing an increase of IL-17 in tumours of Th1 
cell treated mice from day 13 on (*: p < 0.05). B, IL-17 expression data is shown from 
tumours treated with Th1 cells (n = 6), Th1 cells and 500 µg anti-IFN-γ mAb (n = 7), or 
PBS (n = 14). Combined injection of Th1 cells and anti-IFN-γ led to a reduced IL-17 
expression in tumours compared to tumours treated with Th1 cells alone. 
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3.1.4 Tumours are infiltrated by inflammatory cells 
In our tumour model we found an upregulation of inflammatory cytokines in 
tumours of mice treated with Th1 cells. Therefore, we aimed to investigate 
which cells were responsible for the observed upregulation and characterised 
the cellular composition of the inflammatory infiltrate. We performed FACS 
analysis of tumours of Th1 cell treated and PBS treated mice on days 10, 13, 
and 18 after tumour cell injection. Infiltrating CD4+ T cells increased over time in 
tumours of Th1 cell treated mice, peaking on day 18 with a 16-fold increase of 
CD4+ T cells in tumours of Th1 cell treated mice compared to PBS controls 
(Table 27). Surprisingly, we found 5 times more CD8+ T cells in control tumours 
than in tumours of Th1 cell treated mice on day 18, whereas the ratio was 
inverted on day 10. Interestingly, on day 18, CD11b+ cells were found at a three 
times higher level in tumours of Th1 cell treated mice, but still neither F4/80+ 
macrophages nor CD11c+ infiltrating DC were detectable in both groups    
(Table 27). These data suggest that cells of the monocyte/macrophage lineage 
are involved in mediating the therapeutic effects. Since IL-12 and IL-23 are 
mainly produced by monocytes/macrophages [199, 208] and since upregulation 
of IL-12 and IL-23 was detected in tumours of Th1 cell treated mice, these data 
imply an activation of monocytes/macrophages due to Th1 cells and hence, a 
participation of these cells in the therapy by secreting tumour inhibiting 
cytokines within the tumour. 
Table 27. Inflammatory infiltrate of tumours. 
 
Tumours (n = 10/group) from days 10, 13, and 18 after tumour cell injection were 
excised from mice, homogenized, and single cells were stained for different cell 
types. 30000 cells were acquired on the LSRII. Total living cells were gated and the 
percentage of infiltrating cells were calculated on the basis of 10000 cells (*). 
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Consistent with these findings immunohistochemical analysis of tumours of Th1 
cell treated mice on day 18 after tumour cell injection showed a strong increase 
in CD4+ T cells which were homogenously distributed throughout the tumour 
tissue (Fig. 15B). In contrast, in tumours of the control group only a few CD4+   
T cells were detectable (Fig. 15A). Otherwise, only minor differences in tumour 
morphology or necrosis were detectable (Fig. 15C, D). Histology of tumours 
revealed no obvious difference in mast cell occurrence (Fig. 15E, F), suggesting 
that mast cells were not involved in the therapy.  
 
 
Figure 15. Immunohistochemical analysis of tumours. A-F, Serial sections of 
representative tumours (n = 8) of Th1 cell treated and control mice from day 18.          
A, B, Tumours were stained with monoclonal anti-CD4 antibody showing a strong 
increase in CD4+ cells in tumours of Th1 cell treated mice. Arrows: CD4+ cells.            
C, D, Staining with hematoxylin-eosin (H&E, right) showed no major differences in the 
morphology of the tumours. Necrosis (N) was detected in tumours of Th1 cell and PBS 
treated mice. E, F, Toluidin blue staining of tumours showed no difference in mast cell 
occurence. Arrows: Mast cells (purple). Pictures: x 100 magnification. Inlays: x 200 
magnification. 
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Similarly, we found no differences in the proliferation rate between tumours of 
Th1 or PBS treated mice as determined by staining of the cell proliferation-
associated nuclear antigen Ki-67 (Fig. 16). 
 
 
Figure 16. Immunohistochemical analysis of the proliferation rate of tumours. A, Serial 
sections of representative tumours (n = 8) of Th1 cell treated and control mice from  
day 18 were stained with monoclonal anti-Ki-67 antibody. Ki-67 staining showed no 
obvious differences in the proliferation rate of the tumours. Arrows: Ki-67 positive cells. 
Pictures: x 100 magnification. Inlays: x 200 magnification. B, Quantitative analysis of 
(A). Ki-67+ cells out of 500 total cells in tumour sections (n = 60) of Th1 cell and PBS 
treated mice were counted. Error bars denote standard error of the mean (SEM). 
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3.1.5 Tumour vessels are damaged by Th1 cell therapy 
Cytokines such as IL-12 and IL-27 exert strong antiangiogenic properties not 
only due to IFN-γ production and subsequent induction of IP-10/CXCL10 and 
Mig/CXCL9 [192, 193, 218], but also by IFN-γ independent mechanisms      
[181, 219, 234]. As IL-12 and IL-27 were upregulated in tumours of Th1 cell 
treated mice and as tumour growth depends on new blood vessel formation, we 
investigated whether the Th1 cell therapy affected tumour angiogenesis. 
Immunohistological staining with a monoclonal antibody specific for the 
endothelial marker PECAM-1 showed no obvious differences in tumour 
vascularisation with homogenous vascularisation detectable in both groups  
(Fig. 17A-D). However, minor changes in vessel morphology such as clumpy 
and curved structures were observed in tumours of Th1 cell treated mice     
(Fig. 17B, D, arrows). The expression of the most important receptor of 
angiogenesis, VEGFR-2, was not restrained through the Th1 cell therapy since 
most of the tumour vessels were VEGFR-2 positive in both groups (Fig. 17E, F).  
 
 
Figure 17. Tumour vessel staining. A-F, Serial sections of representative (n = 8) 
tumours of Th1 cell treated and control mice from day 18. A-D, Tumours were stained 
with monoclonal anti-PECAM-1 antibody showing homogenous vascularisation in both 
groups. However, minor changes in vessel morphology (arrows) and a minor decrease 
of tumour vessel density were detectable in tumours of Th1 cell treated mice (B, D) 
compared to control mice (A, C). E, F, Staining of tumours with monoclonal anti-
VEGFR-2 antibody revealed no obvious change in the receptor expression pattern 
between both groups. Pictures: x 200 magnification. 
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In contrast, electron microscopy of tumours of Th1 cell treated mice revealed 
endothelial cell death, cytoplasma-enriched endothelia, and vessel obliteration 
(Fig. 18C-E), showing that tumour vessels in Th1 cell treated mice were 
severely impaired. In contrast, tumours in PBS treated mice (Fig. 18A, B) 
showed a typical tumour vascularisation [6, 13, 84]. Moreover, adjacent muscle 
tissue vessels remained unchanged in Th1 cell treated mice (Fig. 18F) 
suggesting that the Th1 cell therapy is restricted to the tumour tissue. Impaired 
vessel structure was associated with enhanced diapedesis in tumour tissue of 
Th1 cell treated mice as sign of inflammation (Fig. 18C, D). 
 
 
Figure 18. Electron microscopy of blood vessels. A, Blood vessels with a bulged 
endothelial cell body (E), tight junctions (arrow), and the basal lamina (labeled by 
asterisks). B, Blood lacuna without limiting endothelial cells but with extracellular matrix 
like collagen fibrils (asterisks) which are located between tumour cells and blood cells. 
C, Blood vessel with leukocyte (L) transendothelial migration. D, Higher magnification 
of (C) showing a transcellularly transmigrated leukocyte still covered by a basal lamina 
(arrow). E, Obliterated vessel. The left arrow labels a tight junction, the right arrow the 
rest of the lumen. F, Vessels in adjacent muscle of Th1 cell treated tumours appear 
normal. In summary, PBS treated (A, B) tumours showed typical tumour 
vascularisation. In contrast, degenerated endothelial cells were observed more 
frequently in tumours of Th1 cell treated mice (C-E). In addition, strong inflammatory 
processes (C, D) and more obliterated vessels (E) were seen in tumours of Th1 cell 
treated mice. Electron microscopy was kindly performed by Prof. Dr. Wolburg, Institute 
for Pathology, Tübingen. 
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3.2 Arresting angiogenesis in vitro and in vivo by increasing 
intracellular ROS levels with dimethylfumarate  
3.2.1 Increasing intracellular ROS with DMF decreases EC proliferation 
and migration in vitro 
DMF in combination with MHF is currently approved for the treatment of 
psoriasis [281]. The molecular basis of action of this compound is not fully 
understood. It has been reported that DMF covalently binds GSH [329]. This 
results in a depletion of GSH, an important intracellular scavenger of ROS. In 
consequence, DMF dose dependently diminished the intracellular GSH levels in 
multiple cells, including human umbilical vein endothelial cells (HUVEC)          
(K. Ghoreschi, R. Heidenreich, unpublished data). Antioxidants such as NAC 
restored intracellular GSH.  
In consequence, DMF treatment of HUVEC should induce intracellular ROS 
levels. Quantification of intracellular ROS showed that DMF dose dependently 
increased intracellular ROS levels in HUVEC (Fig. 19).  
 
 
Figure 19. Intracellular ROS levels after DMF treatment. Representative flow 
cytometric images of intracellular ROS determination in HUVEC after DMF treatment. 
Untreated cells served as a negative control (NC, purple). DMF significantly induced 
the formation of ROS in a dose dependent manner (overlays of NC (purple) with DMF 
(green)). 
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As ROS mediate pro- and antiangiogenic effects, we investigated the influence 
of increasing DMF concentrations on EC proliferation and migration. Endothelial 
cell growth supplement (ECGS)/VEGF induced proliferation of HUVEC         
(Fig. 20A) and human lung-derived microvascular endothelial cells (HLMEC, 
Fig. 20B) was determined by BrdU incorporation and subsequent ELISA. 
Increasing concentrations of DMF dose dependently inhibited the proliferation of 
EC (Fig. 20A, B). At therapeutic doses of DMF (70 µM) EC proliferation was 
even down to background (Fig. 20A, B). 
 
 
Figure 20. DMF inhibits EC proliferation in vitro in a dose dependent manner.           
EC proliferation was determined by BrdU incorporation using ELISA. A, B, DMF 
significantly inhibited proliferation of ECGS/VEGF stimulated HUVEC (A, n = 5) or 
HLMEC (B, n = 4), respectively, in a dose dependent manner. Error bars denote 
standard error of the mean (SEM). (*: p < 0.05 compared to negative control;               
** compared to positive control). 
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Increasing levels of ROS inhibited VEGF-induced proliferation of HUVEC     
(Fig. 21A) and of HLMEC (Fig. 21B) to a similar extend.  
 
 
Figure 21. Inhibition of VEGF-induced EC proliferation by DMF in vitro. EC proliferation 
was determined by BrdU incorporation using ELISA. A, B, DMF inhibited proliferation of 
VEGF stimulated HUVEC (A) and HLMEC (B), respectively. Representative graphs are 
shown. Bars represent the mean of triplicates ± SD (standard deviation). 
Importantly, the inhibition of EC proliferation by DMF was completely reversed 
by the addition of intracellular ROS scavengers such as NAC (Fig. 22A) or 
GSH-OEt (Fig. 22B). In contrast to GSH, GSH-OEt is transported into many cell 
types and is intracellularly hydrolyzed to GSH [330]. These data indicate that 
ROS are important mediators of DMF-induced inhibition of EC proliferation. 
 
 
Figure 22. ROS scavengers reverse the inhibition of proliferation by DMF.        
Proliferation of HUVEC was determined by BrdU incorporation using ELISA. The anti-
proliferative effect of DMF treatment was completely reversed by addition of NAC      
(A, n = 5) or GSH-OEt (B, n = 3). Error bars denote standard error of the mean (SEM).    
(*: p < 0.05 compared to negative control; ** compared to positive control; *** 
compared to ECGS/VEGF+70 µm DMF).  
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As increasing levels of ROS inhibited EC proliferation, we next analysed the 
effects of DMF on EC motility and migration as both are characteristic features 
of angiogenesis. Therefore, we used the scratch-wound assay. HUVEC or 
HLMEC were grown to confluency. Subsequently, a migration gap was created 
(point in time: 0 h). Cells were incubated with low serum as negative control or 
with ECGS/VEGF either alone or in combination with different concentrations of 
DMF. The number of cells migrating back into the migration gap was 
determined microscopically in several independent areas along the wound, on 
the basis of phase-contrast micrographs at 0 h and at 9 h (HUVEC) or 16 h 
(HLMEC) after stimulation (Fig. 23A). 70 µM DMF diminished the migration of 
HUVEC by 50% compared to untreated controls (Fig. 23B) and the migration of 
HLMEC by 35% (Fig. 23C) respectively. 
 
 
 
Figure 23. EC migration in vitro is strongly decreased by DMF. A, Microscopic view of 
migrating HUVEC or HLMEC in the scratch-wound assay. DMF treatment considerably 
inhibited the migration of ECGS/VEGF stimulated HUVEC or HLMEC as compared to 
the negative control. B, C, Quantitative analysis of (A). DMF significantly reduced the 
ECGS/VEGF induced migration of HUVEC by 50% (B, n = 3) and of HLMEC by 35% 
(C, n = 3). Error bars denote standard error of the mean (SEM). (*: p < 0.05 compared 
to negative control; ** compared to positive control). 
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3.2.2 Increasing ROS levels negatively affect EC sprout formation 
in vitro  
To analyse the influence of DMF induced ROS on EC function during the 
complex process of angiogenesis, we performed an in vitro 3-dimensional 
spheroid based sprouting assay that reflects many features of sprouting 
angiogenesis in vivo [313]. HLMEC were stimulated to sprout from microcarrier 
beads and the resulting sprouts were counted microscopically. The number of 
sprouts was strongly reduced by DMF in a dose dependent manner (Fig. 24), 
indicating that sprouting angiogenesis in this model is negatively regulated by 
DMF.  
 
 
Figure 24. In vitro assay of sprouting angiogenesis. HMLEC were grown to confluency 
on cytodex-3 microcarrier beads and embedded in 3-dimensional fibrin gels. VEGF 
mediated strong sprout formation which was significantly inhibited by DMF in a dose 
dependent manner. In contrast, negative controls showed no prominent sprout-
inducing activity (*: p < 0.05 compared to negative control; ** compared to positive 
control). 
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The sprouting capability of HLMEC was completely restored by addition of NAC 
to DMF treated EC (Fig. 25A). The same result was obtained by addition of 
GSH-OEt to DMF treated EC (Fig. 25B). 
 
 
Figure 25. DMF induced inhibition of sprout formation is reversed by ROS scavengers. 
HMLEC were grown to confluency on cytodex-3 microcarrier beads and embedded in 
3-dimensional fibrin gels. The addition of NAC (A, n = 3) or GSH-OEt (B, n = 4) 
completely restored the ECGS/VEGF mediated sprout formation capability of HMLEC, 
whereas NAC or GSH-OEt alone had no influence on the sprout formation. Error bars 
denote standard error of the mean (SEM). (*: p < 0.05 compared to negative control;   
** compared to positive control; *** compared to ECGS/VEGF+70 µm DMF). 
Together, these results strongly suggest that the increase in intracellular ROS 
concentrations plays an important role in mediating the described inhibitory 
effects of DMF on EC functions through inhibition of angiogenesis. 
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3.2.3 Increasing ROS levels prevent EC proliferation without inducing 
apoptosis 
To address whether apoptotic cell death contributed to the DMF triggered 
inhibition of EC proliferation and migration, we analysed apoptosis in HUVEC 
and in HLMEC by Annexin-V/Propidium iodide (PI)-staining and subsequent 
FACS analysis (Fig. 26A, B). We did not detect increased apoptosis, even at 
the highest concentration of 70 µM DMF that resulted in the prominent reduction 
of EC functions. These data show that apoptosis was not critically involved in 
the growth arrest of EC. However, cell cycle analysis suggested a weak G1 
arrest of EC at conditions of high ROS levels (Fig. 26C). 
 
 
Figure 26. DMF has no significant impact on EC apoptosis. A, B, The apoptotic rate of 
HUVEC (A) and HLMEC (B) was determined after DMF treatment by Annexin-V/PI 
staining and subsequent FACS analysis. Dimethyl sulfoxide (DMSO)-treated cells 
served as negative control. Representative graphs out of three experiments are shown. 
Quantification of FACS analysis revealed only a slight increase in the number of 
apoptotic cells even with the highest dose of 70 µM DMF. C, Cell cycle analysis of 
HUVEC was performed using PI staining and subsequent FACS analysis. Data 
suggested a weak G1 arrest of EC due to DMF in 2 out of 4 experiments (M1: % of 
total cells in G0/G1 phase. M2: % of total cells in G2/M phase).  
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3.2.4 Mechanism underlying the inhibition of EC function 
Sustained cellular proliferation is critically dependent on the coordinated action 
of cell cycle progression and cell growth. Furthermore, the VEGF-induced EC 
proliferation requires MAPK-dependent signals. The ERK1/2 MAPK and p38 
SAPK signalling pathways are activated by phosphorylation. These pathways 
are involved in the expression of cell cycle regulated genes and control cellular 
responses [53-55]. Another key role in cell growth and homeostasis plays the 
PI3K target mTOR [56-58].  
Thus, we first analysed the effect of DMF on phosphorylation of p38, ERK1/2 
(p44/p42), and mTOR in HUVEC by Western blot analysis and additionally p38 
by ELISA, to figure out at what point ROS interfere with the intracellular 
signalling cascade. We received divergent results on the phosphorylation of 
ERK1/2, p38, and mTOR ranging from a strong suppression to a moderate 
enhancement, suggesting that these factors are not critically involved in the 
effects of ROS on EC proliferation (Fig. 27). 
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Figure 27. Analysis of the mechanism underlying the inhibition of EC function.             
A-D, Western blot analysis of HUVEC. Representative blots are shown. Cells showed 
divergent results on the phosphorylation of p38, p42/p44, and mTOR ranging from a 
strong suppression (A, C, E) to a moderate enhancement (B, D, F). G, H, Suppression 
(G) and enhancement (H) of the phosphorylation of p38 was also found with ELISA. 
Bars represent the mean of triplicates ± SD. 
In contrast, it was shown that GSH depletion reproducibly inhibited Thr389 
phosphorylation of S6K1, the phosphorylation site which is critical for enzyme 
activation (R. Heidenreich, unpublished data). The PI3K-Akt-S6 kinase pathway 
stimulates protein synthesis essential for endothelial cell cycle progression by 
activation of S6K1 which is a mitogen activated Serine/Threonine protein kinase   
[331, 332]. The detected inhibition was almost down to background levels of 
untreated EC and could be partly restored with NAC. Hence, the PI3K-Akt-S6 
kinase pathway seems to be a target for DMF induced ROS.  
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3.2.5 Increased ROS levels inhibit VEGF-induced neovessel formation  
in vivo 
Since therapeutic doses of DMF significantly inhibit EC proliferation, migration, 
and sprouting angiogenesis in vitro, we asked whether DMF also influences 
neovessel formation in vivo. Hence, we performed the chick chorioallantoic 
membrane (CAM) assay as a model for physiological angiogenesis [60, 314, 
315]. Therefore, a window was cut into the eggshell on embryonic day 3 (E3) 
and the eggs were further maintained at 37°C in humidified air. On embryonic 
day 7 (E7) Whatman filters containing DMSO and/or the appropriate DMF 
concentrations were placed onto the CAMs and incubated for three days. 
Control eggs showed proper neovessel formation indicating that neither the 
experimental conditions nor the solvent DMSO affected the developing 
vasculature (Fig. 28A). In contrast, increasing the intracellular ROS level with 
DMF dose dependently prevented sprouting and branching of small capillaries 
and led to prominent thickening of existing vessels, finally resulting in embryonic 
death (Fig. 28B-E).  
 
Figure 28. In vivo neovessel formation is strongly reduced by DMF treatment.            
A-E, Chorioallantoic membrane assay. Whatman filters containing DMSO and/or the 
indicated concentrations of DMF were placed onto E7 CAMs and incubated for three 
days. A, Filters containing the solvent DMSO served as negative control, showing 
proper angiogenesis in this assay. B, DMF concentrations up to 25 µg had no influence 
on vessels. C-E, Higher concentrations of DMF led to changes in blood vessel 
morphology and lethality of the chicken embryo (C = 50 µg DMF, D = 100 µg DMF,      
E = 250 µg DMF). 
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4 Discussion 
4.1 Tumour-antigen reactive Th1 cells in tumour therapy 
In the current study we investigated the potential of EpCAM-reactive Th1 cells 
for tumour therapy against a conventional tumour-associated antigen, the 
underlying cytokine-mediated, antiangiogenic mechanism, and the possible 
involvement of the host environment. Therefore, we generated non-transgenic 
EpCAM-reactive Th1 cells in vivo, expanded, and characterised them in vitro, 
and confirmed their therapeutic efficiency in a subcutaneous tumour model by 
studying the inhibition of tumour growth with CT26-EpCAM tumour cells in vivo. 
We found that Th1 cell therapy induced the expression of antitumoural IL-23 
and of the antiangiogenic cytokines IL-12 and IFN-γ, all peaking at the initiation 
of tumour growth inhibition. Accordingly, electron microscopy of tumours 
revealed endothelial cell damage and vessel obliteration suggesting that tumour 
vessels in Th1 cell treated mice were severely impaired. Moreover, enhanced 
diapedesis was observed as sign of inflammation. FACS analysis of cells 
infiltrating the tumour suggests that CD11b+ monocytes/macrophages are 
involved in mediating the therapeutic effects. IL-17 may be involved in the 
antitumour effects of the therapy as the expression increased with efficient 
tumour growth inhibition. 
4.1.1 Design and development of an effective, tumour-antigen specific 
Th1 cell therapy 
EpCAM, a human cell surface glycoprotein, was identified as the first human 
tumour-associated antigen in 1979 [333]. It is a pan-epithelial differentiation 
antigen which is restricted to normal epithelia in healthy individuals, but is 
typically overexpressed to varying degrees in most human carcinomas, making 
it an attractive target for tumour therapy [316]. Several clinical trials with 
monoclonal and bi/trispecific antibodies, vaccination strategies, and toxin-
conjugated antibody fragments directed against EpCAM showed variable 
success in the treatment of carcinomas [97]. Hence, we investigated EpCAM as 
a human model TAA to study ACT. Although recent ACT therapies in the clinic 
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show considerably improvements in clinical outcomes for patients, a critical 
point remains the description and generation of tumour-antigen specific 
lymphocytes which are effective in vivo [106]. Adoptive transfer studies defined, 
besides CD8+ T cells, an important role for tumour-specific CD4+ T cells in 
antitumour immune responses [117, 122, 140], especially for Th1 cells        
[138, 139, 142]. Due to the fact that the immunostimulatory TLR9 ligand CpG-
ODN promotes DC IL-12 production and the development of Th1 immunity  
[317, 327, 334-336], in this study we derived non-transgenic EpCAM-specific 
Th1 cells from BALB/c mice that were immunised with CpG1668 and         
CT26-EpCAM carcinoma cells. As we failed to generate Th1 cells in normal 
BALB/c mice, we used IL4-/- BALB/c mice to generate EpCAM-primed Th1 cells. 
Moreover, it was shown that CpG-ODN can act as an in vitro adjuvant by 
enhancing IL-12 production from APC to rapidly generate tumour-specific Th1 
cells [337]. Thus, we used CpG-ODN also in vitro to stimulate CD4+ T cells in 
the presence of EpCAM protein. These tumour-reactive Th1 cells had a strong 
ability to inhibit tumour growth of subcutaneous CT26-EpCAM tumours. We 
found tumour growth inhibition starting between days 10 and 13 after tumour 
cell injection. A similar time is required for successful treatment also in other 
reports of subcutaneous tumour immune rejection [99, 113, 117, 338], 
suggesting that this time is needed to generate efficient antitumour immunity. 
Our experimental design also involved irradiation of the tumour-bearing host 
before administration of Th1 cells as irradiation generally improves efficacy of 
adoptive T cell therapies [113, 171]. Moreover, it was demonstrated that 
irradiation induces an inflammatory response and therefore increases the ability 
of Th1 cells and innate cells to infiltrate solid tumours [171, 339]. In line with 
these reports we found an increased level of proinflammatory cytokines and 
ICAM-1, a strong infiltration of CD4+ T cells, and diapedesis in tumours of Th1 
cell treated mice. In contrast, Th1 cells reacting to OVA had no impact on 
tumour growth. Altogether these results demonstrate the successful 
development of an effective, tumour-antigen specific Th1 cell therapy. 
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4.1.2 Investigating a possible cytokine-mediated mechanism underlying 
the therapy and the involvement of the host environment 
CD4+ T cells also have an important role during the effector phase of an 
immune response which has previously been ascribed to the local release of 
cytokines, especially IFN-γ [142, 152]. Therefore, we analysed the cytokine 
milieu provided by the Th1 cell therapy that might mediate tumour rejection with 
specific emphasis on the role of IFN-γ and cytokines that significantly influence 
Th1 development, inflammation and angiogenesis. We detected an upregulation 
of IFN-γ in tumours of Th1 cell treated mice. IFN-γ, produced by Th1 cells, was 
found to be essential for T cell-mediated tumour regression following ACT in 
several models [99, 139, 158, 179, 213]. These findings are supported by our 
previous results showing that only an adoptive transfer of Th1 cells allowed long 
term control of A20 lymphomas whereas Th2 cells failed [99]. Similarly, many 
others demonstrated that neutralising IFN-γ or the responsiveness to IFN-γ 
diminished the therapeutic efficacy of effector cells [122, 139, 142, 152, 173, 
176, 180] suggesting that the tumour protective effect primarily relies on the 
host immune system. In line with this, EpCAM-reactive T cells were only 
protective against subcutaneous tumours when they failed to produce IL-4; IL-4 
producing T cells did not provide protection (H. Braumüller, unpublished data). 
Surprisingly, in the CT26-EpCAM tumour model injection of anti-IFN-γ mAb 
before adoptive transfer of Th1 cells lead to a significant inhibition of tumour 
growth and was even more effective than Th1 cell treatment alone. This 
correlated with a strong upregulation of IFN-γ mRNA in growth inhibited tumours 
of mice treated with anti-IFN-γ mAb and Th1 cells. In agreement with a recent 
manuscript [326], we assume that the anti-IFN-γ mAb protected the transferred 
Th1 cells from suicide. In summary, our data imply that the IFN-γ secretion of 
EpCAM-reactive Th1 cells is required for an effective therapy and blocking the 
very early IFN-γ responses in the host is able to increase the therapeutic 
efficacy by preventing T cell suicide.  
In addition, we found highly increased levels of IL-23/p19 and an upregulation of 
IL-12/p35, IL-27/Ebi3, and IL-6 in tumours of Th1 cell treated mice suggesting 
an important role for cytokines of the IL-6 family in tumour growth inhibition.  
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This is in line with the findings that IL-12, IL-23, and IL-27 show potent 
antitumour activity in a variety of murine tumour models by further inducing the 
expression of IFN-γ [181, 213, 223, 225, 233]. Nevertheless, there are studies 
suggesting that the antitumour and antimetastatic activity of IL-23 and IL-27 act 
independently of IFN-γ, as these activities were not affected in mice depleted of 
IFN-γ [226, 234]. Moreover, an increased susceptibility to methylcholanthrene 
(MCA)-induced carcinogenesis was found in IL-12/p35-/- and IL-12/p40-/- mice, 
showing that endogenous IL-12 and IL-23 is protective for the growth of 
sarcomas [340].  
Furthermore, the upregulation of IL-23 and IL-6 in tumours of Th1 cell treated 
mice promotes an environment favorable for the survival and proliferation of   
IL-17 producing cells [161, 162, 165, 341]. IL-17 itself induces the expression of 
IL-6, IL-8, TNF-α, and ICAM-1 suggesting an important role for IL-17 in 
localising and/or sustaining an inflammatory response [239]. We analysed the 
possible participation of IL-17 to the antiumoural effect of the therapy. 
Therefore, we first investigated the differentiation of the developing T cells in 
vitro. Analysis of the T cell culture revealed, besides IFN-γ producing cells, a 
population of IL-17 expressing cells. Second, correlating with the expression of 
IL-23/p19, IL-6, and ICAM-1, we found also a significantly increased expression 
of IL-17 in tumours of Th1 cell treated mice on days 13 and 18. Moreover, the 
levels of IL-17 in tumours of mice treated with Th1 cells correlated negatively to 
the levels of IFN-γ and IL-12. These data imply that IL-17 might also be involved 
in the antitumour effects of the therapy.  
Since, besides CD4+ T cells, CTL and innate effector cells such as DC and 
macrophages may be involved in the antitumour effects [199, 207, 223, 235], 
we analysed the participation of the host environment in the inhibition of tumour 
growth. For this purpose, we characterised the cellular composition of the 
tumour infiltrate. First, we found a 16-fold increase of CD4+ T cells in tumours of 
Th1 cell treated mice compared to controls. We believe that it is unlikely that 
CD4+ T cells themselves directly recognized and lysed the tumour cells, as      
in vitro analysis showed that CT26-EpCAM tumour cells are not able to 
stimulate CD4+ T cells in vitro (H. Braumüller, unpublished data). Nevertheless, 
investigations regarding the involvement of apoptosis should be conducted to 
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analyse a potential interaction of CD4+ T cells with the tumour stroma in 
exerting antitumoural effects. Secondly, we could detect CD8+ T cells infiltrating 
the tumours. Surprisingly, we found 5 times more CD8+ T cells in control 
tumours than in tumours of Th1 cell treated mice on day 18 after tumour cell 
injection. Consistent with this result, it has been reported that IL-23 which was 
found to be highly expressed by tumours of Th1 cell treated mice, is able to 
reduce CD8+ T cell infiltration [342]. Moreover, a corresponding downregulation 
of VCAM which is involved in tumour leukocyte recruitment [215, 320], could be 
detected in tumours of Th1 cell treated mice. In summary, these data suggest 
that CD8+ T cells are not required for tumour control in this model. Furthermore, 
although mast cells have been shown to contribute to tumour growth and 
metastasis [343, 344], histology of tumours of both groups revealed no obvious 
differences in mast cell numbers. These data suggest that in this model mast 
cells were not affected by the ACT. Moreover, we were not able to detect a 
change in the percentage of either CD11c+ infiltrating dendritic cells or F4/80 
macrophages. Yet, we found three times more CD11b+ monocytes/ 
macrophages in tumours of Th1 cell treated mice than in PBS treated mice. 
Infiltrating macrophages activated by Th1 cytokines (M1 phenotype), mainly by 
IFN-γ, possess cytotoxic function against tumour cells and produce 
proinflammatory cytokines as shown in several tumour models [117, 122, 139, 
143, 171]. Accordingly, we found that the inflammatory cytokines IL-23 and     
IL-12 were strongly upregulated within tumours of Th1 cell treated mice, 
cytokines that are mainly produced by cells of the monocyte/macrophage 
lineage [199, 208]. Moreover, IL-17 which was found to be expressed in 
tumours of Th1 cell treated mice, recruits cells from the monocyte/macrophage 
lineage into the tumour microenvironment and stimulates the secretion of IL-12 
by macrophages [170, 242] which could mediate the antitumoural effects of    
IL-17. Therefore, summarising these data, we consider that, besides CD4+        
T cells, cells of the monocyte/macrophage lineage in the tumour stroma may 
contribute to the Th1 cell mediated antitumour effects by secreting inflammatory 
cytokines into the tumour stroma and consequently leading to the activation of 
type I polarized immune responses in vivo.  
Furthermore, inhibition of tumour growth may result from 1) the cytotoxic ability  
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of macrophages toward tumour cells, by releasing high levels of toxic 
intermediates such as NO, ROS, and TNF-α [249, 345, 346], 2) the cytotoxic 
and anti-proliferative activity of IFN-γ [188],  and 3) the induction of ischemic-
hemorrhagic necrosis of the tumour by IL-12, through the inhibition of tumour 
angiogenesis [219].  
Summarising these results, we conclude that the therapeutic efficiency of 
adoptively transferred EpCAM-reactive Th1 cells appears to be cytokine-
mediated and dependent on the interaction of Th1 cells with cells of the host 
environment, in particular cells of the monocyte/macrophage lineage.  
4.1.3 Antiangiogenic effects of the therapy 
It is well known that tumours above a critical size induce the formation of new 
blood vessels in the tumour [70]. In consequence, inhibition of angiogenesis 
prevents tumour growth [347]. Hence, antibodies against VEGF [348] or 
VEGFR-2 [349] inhibit tumour angiogenesis in mouse models and several 
studies described that the CD4+ T cell mediated tumour control involves 
antiangiogenic mechanisms [122, 132, 142]. Consistent with a previous report 
[122], in preliminary work we found that only 4 days after the injection of tumour 
cells, CT26-EpCAM tumours were well vascularised and therefore eligible to 
antiangiogenic treatment. Hence, we investigated whether the Th1 cell therapy 
had an effect on tumour angiogenesis. Surprisingly, conventional histology 
showed no obvious differences in tumour vascularisation and revealed only 
minor changes in vessel morphology in tumours of Th1 cell treated mice 
compared to untreated mice. In addition, we could not detect a change in the 
expression pattern of VEGF, the main mediator of angiogenesis. CT26-EpCAM 
tumour cells themselves produce high levels of VEGF in vitro (data not shown). 
This might be the reason why we were not able to reveal smaller differences in 
the regulation of VEGF. Moreover, the expression of VEGFR-2, the most 
important receptor of angiogenesis, PIGF, and the angiopoietins Ang-1 and 
Ang-2 were not strongly affected by the Th1 cell therapy. Supporting the idea 
that the therapy might have an effect on tumour angiogenesis, we found that 
IFN-γ, IL-12, and IL-27 were upregulated in tumours of Th1 cell treated mice. 
These cytokines can exert potent antiangiogenic activity by inducing the 
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production of the two CXC chemokines IP-10/CXCL10 and Mig/CXCL9       
[152, 192, 193, 350] by monocytes/macrophages, fibroblasts, neutrophils [351], 
epithelial cells [352], and endothelial cells [353]. Surprisingly, we could neither 
detect an increased expression of IP-10/CXCL10 and Mig/CXCL9 in our therapy 
model nor a obvious change in the regulation of the appropriate receptor 
CXCR3, suggesting that IFN-γ, IL-12, and IL-27 may act through IP-10/CXCL10 
and Mig/CXCL9 independent mechanims. Previously published data showed 
that these cytokines have also direct effects on EC proliferation and 
differentiation and may impair EC survival [176, 181, 217, 219, 234, 354]. In line 
with this, electron microscopy revealed endothelial cell death and cytoplasma-
enriched endothelia augmented in tumours of Th1 cell treated mice, whereas 
EC in adjacent muscle tissue were not affected suggesting that the Th1 cell 
therapy is restricted to the tumour tissue. Together, the data suggest that IFN-γ, 
IL-12, and IL-27 might act directly on EC in tumour vessels causing severe 
damage to the endothelia. We suggest that IFN-γ, IL-12, and IL-27 exerted anti-
angiogenic effects that contributed to the efficiency of the Th1 cell therapy. 
4.1.4 Conclusion and perspective 
The data presented here suggest that a successful ACT based on CD4+ T cells 
will require: 1) activated tumour antigen specific Th1 lymphocytes, 2) a tumour 
permissive for infiltration of effector cells, 3) an appropriate proinflammatory 
cytokine milieu, and 4) antiangiogenic mediators. Therefore, the detailed 
characterisation of this network leading to tumour growth inhibition or even 
regression might help to develop new cancer treatment strategies which might 
combine active and passive immunotherapy with antiangiogenic treatments. 
Understanding this process should also help to predict which clinical trials will 
be successful in the treatment of cancer.  
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4.2 The antiangiogenic potential of DMF 
In the present study we demonstrated the antiangiogenic potential of GSH-
depletion by DMF, an antipsoriatic compound, conducting in vitro and in vivo 
experiments. DMF strongly influenced the intracellular redox system that 
ultimately resulted in the inhibition of EC function. In vitro, we found that DMF 
significantly reduced proliferation, migration, and sprouting of EC in a dose 
dependent manner without significantly increasing EC apoptosis or cell cycle 
arrest. The application of antioxidants together with DMF completely restored 
EC proliferation and sprout formation after DMF treatment, directly showing that 
ROS were central mediators of DMF induced antiangiogenesis. Detailed 
analysis of involved molecules was unable to show significant inhibition of 
mTOR, ERK1/2, and p38 phosphorylation. Subsequent work by Dr. Heidenreich 
unraveled that phosphorylation of S6K1 downstream of mTOR was severely 
affected by ROS. In vivo, DMF significantly reduced neovascularization in the 
chorioallantoic membrane assay directly proving the in vivo relevance of the     
in vitro findings. 
4.2.1 The effects of DMF on EC function in vitro  
Since Schweckendiek reported an improvement of psoriasis following treatment 
with FAE [280] much research focused on the mode of action of FAE, especially 
on the effects of FAE on T cell differentiation [254]. Although excessive 
angiogenesis significantly contributes to the pathogenesis of psoriasis         
[263, 264], still very little is known about the mechanisms underlying the 
antiangiogenic potential of antipsoriatic drugs such as cyclosporine A          
[257, 355], methotrexate [356], or FAE [357]. The leading compound of FAE is 
DMF which is hydrolysed by esterases to MHF [285, 358]. Therefore, MHF has 
been considered to be the active metabolite [359]. Nevertheless, other groups 
favor DMF as the most effective compound based on the chemical properties of 
DMF that is able to penetrate cellular membranes more easily than MHF     
[285, 360]. Moreover, MHF monotherapies had no clinical effect on psoriasis 
[361]. According to these results we decided to use DMF in our studies to 
further investigate the therapeutic action of FAE on angiogenesis. Moreover, 
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previous work has shown that DMF influences the redox status of cells [282], an 
aspect that critically contributes to the function of EC.  
In several previous studies, therapeutics, established in psoriasis, such as 
Anthralin (the oldest topical therapy) [362], Curcumin (a natural anti-
inflammatory compound) [363], and DMF [282] were shown to diminish 
intracellular GSH levels. One reason might be that GSH forms conjugates with 
a variety of compounds [275]. Accordingly, DMF is able to covalently bind 
intracellular GSH mediated by GSH-S-transferase [329]. As GSH functions as 
intracellular scavenger of ROS and as central redox buffer of the cell, decrease 
of GSH induces oxidative stress. In line with these previous reports, studies 
from our laboratory revealed that GSH depletion by DMF (K. Ghoreschi,          
R. Heidenreich, unpublished data) in HUVEC increased intracellular ROS levels 
in a dose dependent manner.  
EC produce low concentrations of ROS mainly through NAD(P)H oxidase to 
regulate intracellular angiogenic signalling cascades for proliferation, migration, 
and survival [272, 364-366]. Cellular ROS production is important for endothelial 
cell motility as pretreatment of primary HUVEC with NAC abolishes serum-
induced migration [366] and VEGF-stimulated migration and proliferation     
[272, 367] by rapid replenishing intracellular glutathione levels [275]. Hence, the 
question emerges if the increased ROS levels found in HUVEC after DMF 
treatment, are able to affect EC functions such as proliferation and migration 
and whether this may contribute to an efficient therapy. Therefore, we first 
analysed the effects of DMF regarding EC function in vitro. In our studies, we 
used both HUVEC and HLMEC as there are functional differences among EC 
populations that are related to the site of origin (large vessels versus 
microvasculature) [292, 368]. We found a significant inhibition of ECGS/VEGF-
induced EC proliferation and migration which was dependent on increased ROS 
levels. Furthermore, we found that DMF inhibited the VEGF-induced 
proliferation of either HUVEC or HLMEC to the same extend. In addition, DMF 
treatment significantly inhibited sprout formation of HLMEC in vitro. Importantly, 
the DMF-induced inhibition of EC proliferation and sprouting was completely 
reversed through the administration of antioxidants together with DMF showing 
that ROS, exceeding the physiological stimulatory levels, are important 
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mediators of the DMF induced antiangiogenic effect. Nevertheless, the 
increased concentration of ROS on one side and the deficiency of ROS 
scavenger molecules such as GSH on the other side, may both account for the 
formation of oxidative stress. Hence, we cannot distinguish between signals 
directly derived from ROS and indirect signals mediated by ROS scavengers 
contributing to the inhibition of EC function.  
One explanation for the decreased EC functions we found may be that 
depletion of GSH and subsequent exposure to high levels of ROS may induce 
apoptosis or even necrosis [271, 276, 369, 370]. In addition, in different studies 
of Sebök et al. DMF was shown to induce apoptosis in the lymphohistiocytic cell 
line U937 [371] and in HaCaT cells above a concentration of 12 µM [357], 
whereas in other studies, no cytotoxicity of FAE on keratinocytes was detected 
till concentrations of 200-800 µM [372]. Thus, we investigated whether apoptotic 
cell death contributes to the DMF triggered inhibitory effects on EC function. In 
contrast to the previous report [357] we could not detect increased apoptosis 
even at seven times higher concentrations of DMF, up to 70 µM. This result 
implies that apoptosis was not critically involved in the antiangiogenic effects 
mediated by DMF.  
The participation of GSH in the regulation of cell cycle progression might 
represent a further mechanism to inhibit proliferation since intracellular changes 
in the concentration of GSH characterise the cell cycle [271]. In non-oxidant 
stressed cells, basal GSH levels of about 40 nmol/mg protein were detected 
whereas the highest levels of GSH were found in a state of proliferative growth 
[275, 292, 373]. Moreover, GSH provides reducing equivalents that maintain the 
activity of DNA polymerase alpha and ribonucleotide reductase which are both 
crucially involved in DNA synthesis [293-295]. Therefore, depletion of GSH by 
DMF might lead to a cell cycle arrest. Nevertheless, cell cycle analysis of 
HUVEC only suggested a weak accumulation of EC in the G1 phase due to 
DMF treatment suggesting that a cell cycle arrest only rarely contributes to the 
inhibitory effects of DMF on EC function. 
In summary, we conclude that the significant dose dependent inhibition of 
primary EC proliferation, migration, and sprout formation observed in our in vitro 
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studies results from modulation of the intracellular redox system following GSH-
depletion.  
4.2.2 Investigating a possible underlying signalling transduction 
pathway 
We analysed underlying and potentially involved signal transduction pathways 
which are considered to be associated with redox regulation in EC function. It is 
well known that EC use low concentrations of ROS as a second messenger to 
regulate VEGF-induced intracellular angiogenic signalling cascades for 
proliferation, migration, and survival [272, 364-366]. Hence, low concentrations 
of hydrogen peroxide are mitogenic due to the fact that growth factor signalling 
pathways use ROS as second messenger [276, 374]. Moreover, ligand binding 
to receptor tyrosine kinases is important to induce cellular responses by 
phosphorylation of a variety of effector proteins. Accordingly, in EC VEGF-
dependent mitogenesis is mediated by VEGFR-2 activating downstream 
signalling enzymes including the PI3 kinase, MAP kinases (ERK, p38, cJun), 
and the S6 kinases [52, 364, 375-377].  
Therefore, we first investigated whether DMF modulates the activation state of 
the MAP kinases ERK1/2 and p38. ERK and p38 subfamilies of MAPK respond 
to oxidative stress and are therefore able to influence cell survival [53]. The 
ERK1/2 MAP kinase pathway is regulating cell proliferation by controlling cell 
growth and cell cycle progression [53, 54]. This is based on the findings that 
prevention of ERK activation leads to inhibition of cell proliferation [276] and that 
ERK2-/- mice are embryonic lethal [378]. Furthermore, ERK can exert pro- and 
anti-apoptotic effects but it is still unclear what determines these effects [54]. 
The same conflicting results in regulating cell survival were found for p38 [276] 
which is activated by inflammatory cytokines and environmental stress          
[53, 276, 377]. Reflecting these facts, the analysis of the effects of increasing 
ROS levels on phosphorylation of p38 and ERK1/2, revealed divergent results 
ranging from a strong suppression to a moderate enhancement. Importantly, in 
most experiments we found a strong inhibition of p38 or ERK1/2 
phosphorylation; yet, this was not consistently reproducible. 
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Nevertheless, as ERK and PI3K cooperate to activate mTOR promoting cell 
growth and proliferation [57], we next investigated whether phosphorylation of 
the protein mTOR was altered by DMF. As mTOR furthermore represents a cell 
cycle regulatory protein, inhibition of mTOR activity results in cell cycle arrest in 
the G1 phase [56, 57]. We found a weak G1 arrest in EC after DMF treatment 
and detected reduced phosphorylation of mTOR. Yet again, in some 
experiments we found enhanced activation of mTOR suggesting that unknown 
timing problems might hide the effects of increasing ROS levels on mTOR. We 
therefore analysed downstream effectors of mTOR, the ribosomal S61/2 
kinases which control cell size, growth, proliferation, and G1 cell cycle 
progression [331, 332, 377]. Indeed, we found a strong reduction of p70 S6K1 
activation in HUVEC (R. Heidenreich, unpublished data).  
In summary, we could not detect an effect of ROS on mTOR or the intracellular 
signalling cascade of MAPK (p38, p44/42). In contrast, the S6 kinase 1 seems 
to be a target for ROS increases that result from GSH depletion, contributing to 
the antiangiogenic effects mediated by DMF.  
4.2.3 The effect of DMF on angiogenesis in vivo 
As several studies with antipsoriatic drugs such as cyclosporine A and 
methotrexate showed antiangiogenic effects also in vivo [355, 356], we 
investigated the influence of DMF on angiogenesis in an in vivo model. 
Therefore, we performed the CAM assay as a model for physiological 
angiogenesis. We could demonstrate reduced sprouting and branching of 
capillaries as well as blood vessel thickening, indicating that in vivo 
angiogenesis is also negatively influenced by DMF. We also observed lethality 
of the chicken embryos. As several fold higher doses of DMF are perfectly 
tolerated by humans and by mice [281, 285, 379] and as none of the doses 
used locally caused any toxicity in cell cultures, it is most likely that the chicken 
embryos died because of the local disturbance of angiogenesis.  
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4.2.4 Conclusion 
In summary, our study suggested that the antipsoriatic molecule DMF improves 
the chronic inflammatory autoimmune disease psoriasis, besides the previously 
described effects on the immune system, through modulation of the intracellular 
redox system following GSH-depletion. The strong antiangiogenic potential of 
DMF in vitro and in vivo may provide new therapeutic options for the treatment 
of diseases that depend on neovessel formation such as tumour formation, 
aberrant wound healing, or other chronic inflammatory diseases such as 
rheumatoid arthritis.  
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5 Summary 
The aim of this dissertation was to investigate the effects of immune therapies 
on angiogenesis in two different diseases, tumours and psoriasis. 
The objectives in the tumour project were to establish a protective, tumour-
antigen specific Th1 cell therapy and investigate the underlying cytokine-
mediated, antiangiogenic mechanism, and the possible involvement of the host 
environment. Therefore, we generated non-transgenic EpCAM-reactive Th1 
cells in vivo, expanded, and characterised them in vitro. We confirmed their 
therapeutical efficiency in a subcutaneous tumour model using EpCAM 
transfected CT26 carcinoma cells and reached up to 84% reduction of tumour 
weight by day 18 after tumour cell injection. We found significant changes in the 
expression patterns of IFN-γ, IL-12/p35, IL-23/p19, IL-27/Ebi3, IL-6, and IL-17, 
peaking at the initiation of tumour growth inhibition on day 13 after tumour cell 
injection. Accordingly, electron microscopy of tumours revealed endothelial cell 
death and vessel obliteration suggesting that tumour vessels in Th1 cell treated 
mice were severly impaired. Moreover, enhanced diapedesis was observed as 
sign of inflammation. FACS analysis of cells infiltrating the tumour suggests that  
CD4+ and CD11b+ cells are involved in mediating the therapeutic effects. 
The aim of the second project was to investigate the effects of DMF, an 
antipsoriatic compound, on angiogenesis in vitro and in vivo, and identify 
possible underlying signal transduction pathways. We found that DMF 
influenced the intracellular redox system by increasing intracellular ROS levels. 
Increases in ROS resulted in the inhibition of EC function. In vitro, we found that 
DMF significantly reduced ECGS/VEGF induced proliferation, migration, and 
sprout formation of EC in a dose dependent manner without significantly 
increasing EC apoptosis or cell cycle arrest. The application of antioxidants 
such as NAC or GSH together with DMF completely restored EC proliferation 
and sprouting after DMF treatment, showing that ROS were central mediators of 
DMF induced antiangiogenesis. Furthermore, analysing underlying signal 
transduction pathways in vitro, we were unable to show significant effects on 
mTOR, ERK1/2, and p38 phosphorylation. In vivo, DMF significantly reduced 
neovascularization in the chorioallantoic membrane assay, directly proving the 
in vivo relevance of the in vitro findings. 
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Zusammenfassung 
Ziel dieser Doktorarbeit war es, die Auswirkungen von Immuntherapien auf die 
Angiogenese zu untersuchen. 
Im ersten Teil wurden Mechanismen der Tumorantigen-spezifischen Th1 
Zelltherapie untersucht. Es wurde der Einfluss von Zytokinen auf die 
Angiogenese und die Wirtsumgebung des Tumors analysiert. Dazu wurden in 
vivo EpCAM-reaktive Th1 Zellen generiert, in vitro expandiert und 
charakterisiert. Ihr therapeutisches Potential konnte mit Hilfe einer subkutan 
injizierten EpCAM-exprimierenden CT26 Karzinomzelllinie gezeigt werden. Wir 
erzielten eine bis zu 84% Reduktion des Tumorgewichts durch die T-Zell 
Therapie. Es wurden signifikante Unterschiede im Expressionsmuster von    
IFN-γ, IL-12/p35, IL-23/p19, IL-27/Ebi3, IL-6 und IL-17 festgestellt, die an      
Tag 13 nach der Tumorzellinjektion ihren Höhepunkt erreichten. Dies korrelierte 
mit der Initiation der Tumorwachstumsinhibition. Die Elektronenmikroskopie 
zeigte Nekrose von Endothelzellen und Gefäßobliterationen auf. Dies lässt 
darauf schließen, dass die Tumorgefäße durch die Therapie stark geschädigt 
wurden. Auch wurde eine verstärkte Diapedese nachgewiesen. Die FACS-
Analyse der infiltrierenden Zellen ergab, dass CD4+ und CD11b+ Zellen an der 
Therapie beteiligt sind.  
Im zweiten Projekt wurde der Einfluss des Immunmodulators Dimethylfumarat 
(DMF) auf die Angiogenese in vitro und in vivo untersucht, einschließlich 
möglicher Signalwege. DMF erhöhte das intrazelluläre ROS Level. Dies führte 
zu einer Inhibition zahlreicher Endothelzellfunktionen. In vitro, führte die ROS 
Induktion zu einer signifikanten Inhibition der ECGS/VEGF induzierten 
Proliferation, Migration und der Aussprossung von Endothelzellen, ohne die 
Apoptoserate oder den Zellzyklus nachweisbar zu beeinflussen. Antioxidantien 
wie NAC oder GSH stellten die Proliferation und Aussprossung wieder her. Dies 
zeigt, dass erhöhte ROS Spiegel in vitro einen starken antiangiogenen Effekt 
besitzen. Untersuchungen der Signalkaskade führten zu keinem signifikanten 
Einfluss auf die Phosphorylierung von mTOR, ERK1/2 und p38. In vivo 
reduzierte DMF deutlich die Gefäßneubildung im Chorioallantois-Membran-
Assay. Dies belegt die in vivo Relevanz der in vitro Befunde. 
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